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    ABSTRACT  
          INTRODUCTION 
             Pleural effusion is a very common clinical presentation of diseases. A 
correct diagnosis of the underlying disease is essential for the management of 
pleural effusion. Therefore, the first step is to classify them as transudates or 
exudates. Light’s criteria is the most commonly used method . It was found that 
even Light’s criteria misclassified a large number of  effusions , 25% of 
transudates as exudates. 
Hence, there is a need to investigate into new parameters which will 
prove to be superior or supportive to the present available array of tests. Hence, 
this study is being done to evaluate the Efficacy of Total Pleural fluid Bilirubin 
and its ratio to serum Bilirubin levels, Pleural fluid Cholesterol and Pleural fluid 
total Protein level in classifying the  Pleural Effusion as Exudates and 
Transudates and its correlation with Light’s criteria. 
 
AIMS AND OBJECTIVES  
To evaluate the usefulness of Total Pleural fluid Bilirubin and its ratio to serum 
Bilirubin levels, Pleural fluid Cholesterol and Pleural fluid Total Protein level in 
classifying pleural effusions as exudates and transudates. 
    
 
  MATERIALS AND METHODS : 
STUDY POPULATION : 
This study is to be conducted among 50 patients with pleural Effusion , 
attending the Department of  Medicine & Department of  Thoracic Medicine in 
Govt. Rajaji Hospital, Madurai 
STUDY PROTOCOL: 
 Patients with clinical and radiological evidence of pleural effusion are 
to be included in the study.Then  they are classified in to exudates and 
transudates on the basis of the clinical , radiological and biochemical 
evaluation . 
 Pleural fluid bilirubin & Serum Bilirubin , Pleural fluid cholesterol, 
Pleural fluid total protein are estimated and the patients are classified 
in to exudates and transudates. Then the patients are classified in to 
exudates and transudates on the basis of Light’s criteria. 
 Now the classification of exudates and transudates done on the basis 
of Total Pleural fluid bilirubin and its ratio to serum bilirubin  , Pleural 
fluid cholesterol , Pleural fluid Total protein are compared with results 
of the classification of exudates and transudates done on the basis of  
Light’s criteria. 
 Sensitivity , specificity , Positive predictive value , negative predictive 
value ,  diagnostic accuracy of each testsare calculated . 
RESULTS : 
From our study we came to known that there was no statistically significant 
difference among various criterias in classifying pleural effusion as exudates 
and transudates. The misclassification of exudates and transudates by various 
criteria when compared to Light’s criteria is not statistically significant as p 
value is <0.05. 
CONCLUSION : 
From our study we came to a conclusion that to classify an exudative pleural 
effusion from a transudative pleural effusion  
- most specific test is pleural fluid total protein and  
- most sensitive test is pleural fluid / serum bilirubin ratio .  
The positive predictive value, negative predictive value and diagnostic accuracy 
is higher for pleural fluid total protein . 
To conclude, though Light's criteria remains as gold standard to differentiate 
transudates and exudates, in cases where there is a mismatch between clinical 
diagnosis and the outcome from Light's criteria, pleural fluid bilirubin / serum 
bilirubin ratio and pleural fluid total protein evaluation may add to the 
diagnostic accuracy.  
KEYWORDS : Pleural fluid , bilirubin ,cholesterol , pleural fluid total protein, 
Light’s criteria ,exudates , transudates 
 INTRODUCTION 
 
             Pleural effusion is a very common clinical presentation of diseases. 
A correct diagnosis of the underlying disease is essential for the management 
of pleural effusion. A limited number of diseases causes transudative pleural 
effusions, whereas exudative effusions require more extensive diagnostic 
investigations. Therefore, the first step is to classify them as transudates or 
exudates, even if this differentiation does not contribute to the etiological 
diagnosis.  
Many criteria have been used to distinguish them, but none of them 
have been found to be satisfactory. Light’s criteria is the most commonly 
used method  
 The criteria is one or more of the following for diagnosing  exudates. 
1.pleural fluid protein /serum protein >0.5 
2.pleural fluid LDH/serum LDH >0.6 
3.pleural fluid LDH more than 2/3 rd of the upper limit of 
serum. 
It was found that even Light’s criteria misclassified a large 
number of  effusions , 25% of transudates as exudates. 
 
  
Hence, there is a need to investigate into new parameters which will 
prove to be superior or supportive to the present available array of tests. 
Many other biochemical markers like bilirubin, cholesterol, and albumin are 
there. 
 
Hence, this study is being done to evaluate the Efficacy of Total 
Pleural fluid Bilirubin and its ratio to serum Bilirubin levels, Pleural fluid 
Cholesterol and Pleural fluid total Protein level in classifyingthe  Pleural 
Effusion as Exudates and Transudates and its correlation with Light’s 
criteria. 
 
 
 
 
 
 
 
 
  
AIMS AND OBJECTIVES  
 
To evaluate the usefulness of Total Pleural fluid Bilirubin and its ratio to 
serum Bilirubin levels, Pleural fluid Cholesterol and Pleural fluid Total 
Protein level in classifying pleural effusions as exudates and transudates. 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
 
Definition 
Pleural effusion is defined as the abnormal accumulation of pleural fluid 
within the pleural cavity. Crucial feature of the breathing apparatus is the 
pleural space. This is a potential space between the parietal pleura and the 
visceral pleura It is the coupling system between the lung and the chest wall .  
ANATOMY OF PLEURA  
The lung parenchyma, the diaphragm , the mediastinum and the rib cage are 
covered by a serous membrane called the pleura. Pleura is divided into 
visceral pleura and parietal pleura. At the lung root , the visceral and parietal 
pleura meet. 
Visceral pleura : 
It covers the lung parenchyma in its points of contact with the diaphragm , 
the mediastinum and the chest wall and also in the interlobar fissures. 
Parietal pleura : 
It lines inside of the thoracic cavities.  
It is subdivided on the basis of intrathoracic structures that it lines in to  
 
 1. Costal parietal pleura ,  
2. Mediastinal parietal pleura,  
3. Diaphragmatic parietal pleura. 
Pulmonary ligament : 
This is a thin double fold of pleura formed due to the downward extension of 
the pleura , posterior to the lung root. 
Pleural space : 
This is a potential space between the the visceral pleura and parietal pleura. 
Pleural fluid : 
This is a thin film of fluid  normally present in between the visceral pleura 
and parietal pleura ie., pleural space 
Functions of pleural fluid  - acts as a lubricant . During the respiratory 
movements the pleural fluid allows the visceral pleura which is covering the 
lung to slide along the parietal pleura which is lining the thoracic cavity. 
 
 
 
 
  
HISTOLOGY OF PLEURA : 
Parietal pleura  - composed of loose , irregular connective tissue which is 
covered by a single layer of mesothelial cells. Within the pleura there are 
blood vessels , mainly capillaries and lymphatic lacunas. Endothoracic fascia 
is situated  deeper to parietal pleura. This is a continuous dense band of 
irregular connective tissue. This is mainly composed of elastin and collagen 
and it covers ribs and intercostal spaces. 
Visceral pleura – composed of two layers namely the mesothelium and the 
connective tissue. 
Connective tissue layer functions : 
1. Contributes to elastic recoil of lung ,helps in expelling air from the 
lung 
2. Restricts the volume of lung to which the lung can be inflated , and 
thereby protecting the lung  
Mesothelialcells  functions :  
It forms a monolayer of pavement like cells lining the pleural surfaces. 
1. Movement and transport of particulate matter and fluid across the 
pleural surfaces . 
 2. Migration of leucocytes in response to inflammation . 
3. Synthesis of cytokines , growth factors , EC matrix proteins . 
4. Antigen presentation and transformation to myofibroblasts . 
Blood supply : 
Parietal pleura receives blood supply from systemic capillaries such as 
intercostal artery ,pericardiophrenic artery , superior phrenic and 
musculophrenic artery  and drained by intercostal veins , phrenic veins. 
Visceral pleura : Blood supply of thin pleura is derived from pulmonary 
circulation , and that of thick pleura is derived from bronchial arteries. 
Venous drainage is through the pulmonary veins. 
Lymphatic drainage : 
Lymphatic plexus in the parietal pleura drains in to intercostal 
,mediastinal, tracheobronchial , parasternal and phrenic nodes. 
In the parietal pleura the lymphatic vessels are in communication with the 
stomas, the diameter of which ranges between 2 to 6 microns.  The main 
pathways for the elimination of particulate matter is the stomas with 
lacuna and lymphaticsvessels . 
In the visceral pleura there are abundant lymph vessels which joins 
bronchial lymph vessels. 
 Nerve supply : 
Intercostal nerves supply the costal and peripheral part of diaphragmatic 
pleura. So the pain sensation due to inflammation of this pleura is 
perceived in the chest wall. 
Phrenic nerve supplies the central part of diaphragmatic pleura . So when 
this part of pleura is irritated or inflamed the pain is felt in the ipsilateral 
shoulder.   
 
PHYSIOLOGY OF PLEURA  
Formation of the Pleural Fluid : 
Pleural fluid can originate in the  
 pleural capillaries,  
 the intra-thoracic lymphatics,  
 the intrathoracic blood vessels, 
 the peritoneal cavity , or 
 the interstitial spaces of the lung,  
 
 
Pleural Capillaries 
Starling's law of transcapillary exchange governs the movement of fluid 
between the pleural capillaries and the pleural space . 
  
Hydrostatic pressure : 
In the parietal pleura , the hydrostatic pressure is approximately 30 cm 
H2O,but  the pleural pressure is approximately -5 cm H2O. The net 
hydrostatic pressure is therefore 30 - (-5) = 35 cm H2O .This pressure favors 
the movement of fluid from the capillaries in the parietal pleura to the pleural 
space.   
 
Oncotic pressure : 
This hydrostatic pressure gradient is  opposed by oncotic pressure gradient. 
Plasma oncotic pressure is approximately 34 cm H2O.  
Normally, the pleural fluid has an oncotic pressure of approximately 5 cm 
H2O, as it contains a small amount of protein .The  net oncotic pressure 
gradient is 34 - 5 = 29 cm H2O. Thus, the net gradient is 35 - 29 = 6 cm H2O. 
It favours the movement of fluid to the pleural space from the capillaries in 
the parietal pleura. 
The net gradient for fluid movement across the visceral pleura in 
humans is probably close to zero, which has not been demonstrated. The 
pressure in the parietal pleural capillaries is approximately 6 cm H2O more 
than that in the visceral pleural capillaries.  
This is  because the visceral pleural capillaries is drained by the 
pulmonary veins.  Also this is the only pressure that differs from those 
 pressure affecting fluid movement across the parietal pleura. The net 
gradient for the parietal pleura is 6 cm H2O. So the net gradient is 
approximately zero for the  fluid movement across the visceral pleura. 
 The capillaries in the visceral pleura when compared to those in the parietal 
pleura , are much farther from the pleural space .So  the filtration coefficient 
(Lp) for the visceral pleura is substantially less than that for the parietal 
pleura . 
When compared with the intercostal spaces ,the fluid formation  is 
more across the parietal pleura over the ribs. Also fluid formation was more 
over the caudal ribs than over the cranial ribs.  But in contrast, pleural liquid 
absorption was more primarily in the parietal pleura adjacent to the 
intercostal space rather than in the parietal pleura overlying the ribs. The 
formation of pleural fluid was more, if the breathing frequency was 
increased. 
 
Interstitial Origin 
It has been demonstrated that the  interstitial spaces of the lungs, is the origin 
of much of the fluid that enters the pleural space. Pleural fluid accumulates if 
there is either high-pressure or high-permeability pulmonary edema.The  
elevation in the wedge pressure is directly related to the amount of pleural 
fluid formed. But only after the development of pulmonary edema, increases 
in pleural fluid accumulation occur. 
 In patients with congestive heart failure , the origin of the pleural effusion is 
probably the pulmonary interstitial space. 
It is likely that many conditions associated with lung injury, such as lung 
transplantation and pulmonary embolization , the origin of the pleural fluid is 
also the interstitial spaces of the lung. 
It has been shown that the subpleural interstitial pressure increases, with 
increasing levels of interstitial fluid. Even though the visceral pleura is thin, 
the barrier to the movement of fluid across the visceral pleura appears to be 
weak. Therefore, once there is increase in  subpleural interstitial pressure, the 
fluid will enter to the pleural space through the visceral pleura. 
 
Peritoneal Cavity 
If there is free fluid in the peritoneal cavity,  pleural fluid accumulation can 
occur. Peritoneal fluid enters the pleural space through the openings in the 
diaphragm. Since the pressure in the pleural cavity is less than the pressure 
in the peritoneal cavity the fluid will flow from the peritoneal space to the 
pleural space. In the following conditions like hepatic hydrothorax, Meigs'  
syndrome, and peritoneal dialysis, the peritoneal cavity is the origin of the 
pleuralfluid. 
 
 
 
 Thoracic Duct or Blood Vessel Disruption 
If there is disruption of thoracic duct, there is accumulation of lymph in the 
pleural space.Thiswill  produce a chylothorax. With chylothorax the rate of 
fluid accumulation can be more than 1,000 mL/day. 
 
Origin of Normal Pleural Fluid 
It is believed that the fluid that normally enters the pleural space originates in 
the capillaries in the parietal pleura. 
The amount of pleural fluid formed daily is approximately 15 mL in a 50-kg 
individual. Since  in the interstitial spaces the protein level is normally 
approximately 4.5 g/dL, and the protein level in normal pleural fluid is only 
approximately 1 to 1.5 g/dL, the origin of the fluid does not appear to be the 
interstitial spaces of the lung . Pleural fluid with lower protein levels are 
produced by higher vascular pressures . Evans blue dyed albumin  studies 
with rabbits have demonstrated that most fluid originates in the parietal 
pleura over the ribs . 
 
 
 
 
 
 
 Pleural Fluid Absorption 
Lymphatic Clearance 
The lack of fluid accumulation in normal individuals is due to the clearance 
of fluid through the pleural lymphatics. By means of stomas in the parietal 
pleura , the pleural space is in communication with the lymphatic vessels in 
the parietal pleura. Visceral pleura lacks such stomas. The lymphatics in the 
parietal pleura, removes proteins, cells, and all other particulate matter from 
the pleural space. The carbon particles exit the pleural space through the 
stomas ,where the mesothelial cells are small and not flattened . These stoma  
increases in diameter in response to increased levels of nitric oxide in the 
pleural space. 
In a 60-kg individual the lymphatic drainage from each pleural space is on 
the order of 20 mL/hr or 500 mL/day.  
Once the volume of the pleural liquid exceeds a certainthreshold, the 
lymphatics operate at maximum capacity. The capacity for lymphatic 
clearance is 28 times as high as the normal rate of pleural fluid formation. 
 
Clearance through Capillaries in Visceral Pleura 
Until the mid-1980s, it was thought that the capillaries in the visceral pleura 
in humans is the primary route for the exit of fluid from the pleural space. 
 
 
 Through the lymphatics in the parietal pleura almost all the pleural fluid is 
removed. Several hundred milliliters of water probably traverse the pleural 
membranes each day. Since the osmolarity is nearly identical on each side of 
the membrane , the net movement is of only a few milliliters. 
 
Alternative Mechanisms for Pleural Fluid Removal 
In  the removal of protein from the pleural space , transcytosis plays a role 
and there is some evidence for that. Only 29% of the overall removal of 
albumin occurred through the stoma with small hydrothoraces, while 64% of 
the albumin from large hydrothoraces was removed through the stoma 
 
Pathogenesis of Pleural Effusions 
Whenever the rate of pleural fluid formation exceeds the rate of pleural fluid 
absorption, there is accumulation of pleural fluid.  
Normally, from the capillaries in the parietal pleura, a small amount (0.01 
mL/kg/hour) of fluid constantly enters the pleural space. The lymphatics in 
the parietal pleura removes  almost all of this fluid . Lymphatics have a 
capacity to remove at least 0.20 mL/kg/hour. The lymphatics remove the 
fluid exceeding the normal rate of fluid formation by a factor of 20.  
 
 
 
 GENERAL CAUSES OF PLEURAL EFFUSION : 
A.Increased pleural fluid formation : 
1.Increased interstitial fluid in lungs  
 - Left ventricular failure , 
- Pneumonia , 
- Pulmonary embolism 
2. Decreased pleural pressure 
- Lung atelectasis  
 - Lung elastic recoil is increased 
3.Increased permeability of pleural capillaries  
 -  Pleural inflammation , 
 - Elevated vascular endothelial growth factor levels 
4.Increased levels of protein in the pleural fluid 
5. Increased intravascular pressure in pleura 
 -  Right or left ventricular pressure , 
 - Superior vena cava syndrome 
6.Distruption of thoracic blood vessels 
7.Thoracic duct distruption 
8.Increased fluid in the peritoneal cavity 
- Peritoneal dialysis  
 - Ascites 
 
 B.Decreased pleural fluid absorption 
1.Obstruction of pleural lymphatic drainage 
2.Distruption of aquaporin system in the pleura 
3. Elevated systemic vascular pressure 
- Superior vena caval syndrome  
- Right ventricular failure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.Increased Pleural Fluid Formation 
Whenever there is increased pulmonary interstitial fluid or when one of the 
terms in Starling's equation is changed , there is increased pleural fluid 
formation . 
 
a) Increased Interstitial Fluid 
Increased interstitial fluid in the lungs is the most common cause of 
increased pleural fluid formation . As mentioned earlier, irrespective of 
whether the edema is due to low-protein fluid  or high-protein fluid, pleural 
fluid accumulates, whenever the amount of edema in the lung exceeds 5 
g/gram of dry lung weight. In conditions like congestive heart failure, 
parapneumonic effusions, acute respiratory distress syndrome, and in those 
who have undergone lung transplantation , this appears to be the 
predominant mechanism for the accumulation of pleural fluid. 
 
b) Increased Hydrostatic Pressure Gradient 
Through Starling's equation ,there will be an increase in the rate of pleural 
fluid formation , if there is an increase in the gradient between the 
intravascular pressure and the pleural pressure.  
 
 
 
 In conditions like right ventricular failure, left ventricular failure, pericardial 
effusions, or superior vena cava syndrome, there is increase in the 
intravascular pressure. Atelectasis of the lower lobe or complete lung due to 
bronchial obstruction is the most common situation producing a decrease in 
the pleural pressure.  When the visceral pleura becomes coated with a 
collagenous peel and the lung becomes trapped, a decrease in the pleural 
pressure also occurs.  The pleural pressure can become very negative, in 
these instances ie.,it goes  below -50 cm H2O . Diseases in which the elastic 
recoil of the lung is increased, the decreased pleural pressures can also 
contribute to pleural fluid accumulation. 
 
c) Increased Capillary Permeability 
If the pleural surfaces become inflamed, the permeability of the capillaries 
may be increased . The permeability of the capillaries is increased by  
increased levels of vascular endothelial growth factor (VEGF) .This  may be 
at least partially responsible for the accumulation of pleural fluid. 
Mesothelial cells have VEGF receptors on their surface which have been 
demonstrated. In exudative effusions the levels of VEGF are higher when 
compared to  transudative pleural effusions .  
 
 
 
 d) Decreased Oncotic Pressure Gradient 
In conditions likehemothorax, increased - permeability pulmonary edemaand 
with conditions in which the pleural capillary permeability is increased, the 
levels of pleural fluid protein is increased. The capacity to remove pleural 
fluid by the lymphatics is approximately equal to the rate of formation of 
pleural fluid. Moreover, a very uncommon cause of pleural effusionis  
hypoproteinemia. 
 
e) Presence of Free Peritoneal Fluid, or Disruption of the Thoracic 
Duct or anIntrathoracic Blood Vessel : 
The free fluid in the peritoneal cavity traverse through the holes in the 
diaphragm and  it will lead to pleural fluid accumulation and pleural 
effusion. In a similar manner, if there is a disruption in the thoracic duct, 
chyle will accumulate in the pleural space .  And if there is a disruption of a 
blood vessel in the thorax , blood will accumulate in the pleural space . 
 
2.Decreased Pleural Fluid Absorption 
 
a) Normal Pleural fluid absorption by lymphatics 
Normally, the lymphatic flow from the pleural space is approximately 0.01 
mL/kg/hour or 15 mL/day because this is the amount of pleural fluid formed. 
 However, the capacity of the lymphatics is approximately 0.20 mL/kg/hour 
or 300 mL/day. 
 
b) Obstruction of Lymphatics 
Obstruction of the lymphatics draining the parietal pleura is the most 
common cause of  decrease in pleural fluid absorption .In the development of 
a malignant pleural effusion , lymphatic blockade is an important factor . 
 
c) Elevation of Systemic Venous Pressures 
When there is elevation of the pressures in the central veins , lymphatic flow 
will be decreased.  This is because the lymphatics drain into the systemic 
venous circulation . 
The pleural effusions developed because of (a) leakage of lymph out of the 
lymphatics that pass through the chest (these include the diaphragmatic and 
pulmonary lymphatics and thoracic duct ) ; or (b) leakage of interstitial fluid 
into the pleural space due to obstruction of lung or chest wall lymphatics . 
 
 
 
 
 
 
  
CLINICAL MANIFESTATIONS OF PLEURAL EFFUSION : 
Normally, only a few milliliters of pleural fluid is present in the pleural 
space. If fluid in the pleural space is detected on a radiologic examination, it 
is abnormal. Pleural fluid accumulation is associated with many conditions . 
When pleural fluid is detected, an effort should be made to determine the 
etiology . 
1. Symptoms 
In a patient with pleural effusion , symptoms  mainly depends on the 
underlying process causing the effusion . Many patients have no symptoms 
referable to the effusion. When symptoms are related to the effusion, they 
arise either from inflammation of the pleura, from compromise of pulmonary 
mechanics, from interference with gas exchange, or on rare occasions, from 
decreased cardiac output. 
a) Pleuritic chest pain  
Normally visceral pleura does not have pain fibers , only the parietal pleura 
contains pain fibers . In a patient with  pleural effusion , pleuritic chest pain  
always indicates inflammation of the pleura, specifically parietal pleura . 
Some patients with pleural effusions experience a dull, aching chest pain 
rather than pleuritic chest pain. 
The parietal pleura is innervated mostly by the intercostal nerves. So, the 
pain associated with pleural disease is well localized and it  coincides with  
  
the area of the pleura which is affected by disease . Since the intercostal 
nerves are also distributed to the abdomen ,pleuritic  pain is referred to the 
abdomen .When the central portion of the diaphragmatic pleura is involved, 
there are exceptions to the localization of the pain . Phrenic nerve  is the 
nerve supply to this portion of the parietal pleura . Pain  is referred to the tip 
of the ipsilateral shoulder , if the central portion of the diaphragm is 
inflammed.  
Pathognomonic of diaphragmatic involvement is pleuritic pain felt 
simultaneously in the lower chest and ipsilateral shoulder. 
b) Cough  
A dry, nonproductive cough is the  second symptom of pleural effusion. 
Although it may be related to pleural inflammation ,the exact  mechanism 
producing the cough is not clear. Alternately, cough reflex is stimulated by 
the pleural fluid   compressing the lung , bringing the opposing bronchial 
walls into contact. 
c) Dyspnea 
Dyspnea  is the third symptom of pleural effusion . As pleural effusion acts 
as a space-occupying process in the thoracic cavity , it cause dyspnea by 
reducing  all subdivisions of lung volumes. 
This explains the small increase in pulmonary function following therapeutic 
thoracentesis if pleural effusion is associated with parenchymal disease . The 
 degree of dyspnea is frequently out of proportion to the size of the pleural 
effusion. Due to the weight of fluid on the diaphragm , the diaphragmatic 
function is compromised and this results in dyspnea . 
 
2. Physical Examination 
a) Inspection  
When the chest of a patient with pleural effusion, or who is suspected of 
having a pleural effusion is examined, particular attention should be paid to 
the relative sizes of the hemithoraces and the intercostal spaces.  
Depending upon the pleural pressure clinical findings vary . The 
ipsilateralhemithorax will be larger, and the usual concavity of the intercostal 
spaces will be blunted or even convex, if the pleural pressure on the side of 
the effusion is increased. In contrast, the ipsilateralhemithorax will be 
smaller, and the normal concavity of the intercostal spaces will be 
exaggerated , if the pleural pressure on the side of the effusion is 
decreased.This occurs  with obstruction of a major bronchus or a trapped 
lung. In addition, the intercostal spaces retract, with inspiratory efforts. 
An indication of therapeutic thoracentesis is enlargement of the hemithorax 
with bulging of the intercostal spaces. This is done to relieve the increased 
pleural pressure. Of course, the hemithoraces are equal in size and the 
intercostal spaces are normal, in many patients with pleural effusions. 
 
 b) Palpation  
To delineate the extent of the effusion , palpation of the chest in patients with 
pleural effusions is useful. Tactile fremitus is absent or attenuated, in areas 
of the chest where pleural fluid separates the lung from the chest wall.This is 
because the vibrations emanating from the lung are absorbed by the fluid . 
To  identify the upper border of the pleural fluid , tactile fremitus is much 
more reliable than percussion. It is also useful to identify a proper site to 
attempt a thoracentesis. Tactile fremitus is much more reliable than 
percussion , because with a thin rim of fluid, the tactile fremitus is 
diminished, but the percussion note may still be resonant.  
Apical impulse  
Palpation may also reveal that the apical impulse is shifted to one side or the 
other. The apical impulse may not be palpable, in patients with large left 
pleural effusions.  
Position of trachea 
The position of the trachea in patients with pleural effusions, always 
indicates the relationship between the pleural pressures in the two 
hemithoraces. 
c) Percussion  
In a patient with pleural effusion the percussion note over the area of 
involvement is dull or flat. At the lung bases where the thickness of the fluid 
is the greatest, the dullness is maximum. As mentioned earlier, if only a thin 
 rim of fluid is present, the percussion note may not be duller. For identifying 
small amounts of pleural fluid, light percussion is better than heavy 
percussion. 
d) Auscultation  
Auscultation over the area of pleural effusion characteristically reveals 
decreased or absent breath sounds. However,breath sounds may be 
accentuated and take on a bronchial characteristic, near the superior border 
of the fluid. 
This accentuation of breath sounds does not mean that an associated 
parenchymal infiltrate is present.  
Pleural rub  
Auscultation may also reveal a pleural rub. Pleural rubs are most commonly 
heard during the latter part of inspiration and the early part of expiration, and 
are characterized by coarse, leathery, creaking sounds producing a to-and-fro 
pattern of sound. The rubbing together of the roughened pleural surfaces 
during respiration, causes pleural rubs. Pleural rubs are often associated with 
local pain on breathing that subsides with breath-holding. Pleural rubs often 
appear as pleural effusions diminish in size, either spontaneously or as a 
result of treatment, because the pleural fluid is no longer present between the 
roughened pleural surfaces. 
It is important to realize that , all the classic physical findings associated 
with a pleural effusion can be produced by an elevated hemidiaphragm.  
  
Obviously, while evaluating a patient with a pleural effusion ,the chest is not 
the only structure that should be examined. Because  clues to the origin of 
the effusion are often present elsewhere.  
 
Here are some of the causes of pleural effusion and their clinical findings 
that are helpful in the diagnosing the patient. 
Systemic cause and clinical findings : 
1. If the patient has cardiomegaly, neck vein distension, or peripheral 
edema, the effusion is probably due to congestive heart failure (CHF) . 
2. The pleural effusion is due to rheumatoid disease or lupus 
erythematosus (LE) if the patient has signs of joint disease or 
subcutaneous nodules . 
3. Metastatic disease, as do breast masses is suspected as the cause of 
pleural effusion if there is an enlarged, nontender nodular liver or the 
presence of hypertrophic osteoarthropathy.  
4. In patients with subdiaphragmatic pathology there will  be abdominal 
tenderness.  
5. Tense ascites suggests cirrhosis and a hepato thorax. 
6. Lymphoma, sarcoidosis or metastatic disease should be suspected if 
there is lymphadenopathy. 
 
 DIFFERENTIAL DIAGNOSIS OF PLEURAL EFFUSION : 
I. Transudative pleural effusions  
A. Congestive heart failure  
B. Cirrhosis  
C. Nephrotic syndrome  
D. Cerebrospinal fluid leaks to pleura  
E. Hypoalbuminemia 
F. Sarcoidosis 
G. Peritoneal dialysis  
H. Glomerulonephritis  
I. Myxedema 
J. Superior vena caval obstruction  
K. Fontan procedure  
L. Urinothorax 
 
II. Exudative pleural effusions  
A. Neoplastic diseases  
1. Metastatic disease  
2. Mesothelioma  
3. Pyothorax-associated lymphoma 
 4. Body cavity lymphoma  
B. Infectious diseases  
1. Bacterial infections  
2. Tuberculosis  
3. Viral infections 
4. Parasitic infections  
5. Fungal infections  
C. Pulmonary embolization  
D. Gastrointestinal disease  
1. Pancreatic disease  
2. Subphrenic abscess  
3. Intrahepatic abscess  
4. Heart diseases Postcoronary artery bypass graft surgery  
5. Postcardiac injury (Dressler's) syndrome  
6. Pericardial disease  
7. Diaphragmatic hernia  
8. Endoscopic variceal sclerosis  
9. Postliver transplant 
10. Pulmonary vein stenosis postcatheter ablation of atrial 
fibrillation 
11. Intrasplenic abscess  
12. Esophageal perforation  
 13. Postabdominal surgery  
E.Obstetric and gynecologic disease  
1. Ovarian hyperstimulation syndrome  
2. Fetal pleural effusion  
3. Endometriosis 
4. Postpartum pleural effusion  
5. Meigs' syndrome  
F.Collagen vascular diseases  
1. Rheumatoid pleuritis 
2. Systemic lupus erythematosus 
3. Familial Mediterranean fever  
4. Churg-Strauss syndrome  
5. Wegener's granulomatosis 
6. Drug-induced lupus  
7. Immunoblastic lymphadenopathy  
8. Sjogren's syndrome  
G.Drug-induced pleural disease  
1. Ergot drugs  
2. Amiodarone 
 3. Interleukin 2  
4. Nitrofurantoin 
5. Dantrolene 
6. Methysergide 
7. Procarbazine 
8. Clozapine 
9. Methotrexate  
H.Miscellaneous diseases and conditions  
1. Sarcoidosis 
2. Uremia 
3. Trapped lung  
4. Acute respiratory distress syndrome  
5. Whipple's disease  
6. Iatrogenic pleural effusions 
7. Asbestos exposure  
8. Postlung transplant  
9. Postbone marrow transplant  
10. Yellow nail syndrome  
11. Electrical burns  
 
 12. Extramedullaryhematopoiesis 
13. Rupture of mediastinal cyst  
14. Therapeutic radiation exposure  
15. Drowning  
16. Amyloidosis  
17. Milk of calcium pleural effusion  
I.Hemothorax 
J. Chylothorax 
 
 
 
 
 
 
 
 
 
 
 GENERAL TESTS TO DIFFERENTIATE THE CAUSES OF 
EXUDATIVE PLEURAL EFFUSION : 
1.Appearance of the fluid : 
Mostly transudative and many exudative pleural effusions are clear , straw 
colored , nonviscid and odourless. 
The red colour of the fluid indicates the presence of blood. To confirm 
hemothorax we have to do a hematocrit. If the hematocrit of the pleural fluid 
was more than 50 % of the peripheral blood hematocrit , then it is a 
hemothorax. When the pleural fluid is blood tinged  the RBC count is 5000 
to 10000 / mm3 . If the pleural fluid macrophages contain haemoglobin 
inclusions , then it indicates that the blood was present before thoracentesis 
and the blood is not due to traumatic tap. 
Increased lipid content or increased cellular content both can make pleural 
fluid to appear turbid . If after centrifuge the supernatant fluid remains turbid 
then it is due to lipid content. But if the supernatant fluid is clear , then the 
turbidity is due to cellular debris . 
Amebiasis with a  hepatopleural fistula – chocolate sauce or anchovy paste. 
The mixture of blood ,cytolysed and normal liver tissue make this 
appearance. 
 
 Malignant mesothelioma – high viscocity due to elevated  hyaluronic acid . 
Anaerobic bacterial infection – feculent odour 
Urinothorax – smell of urine 
2.WBC count : 
Most transudates have WBC count below 1,000/mm3 and exudates have 
more than 1,000/mm3. 
WBC count > 10,000/mm3 – parapneumonic effusions 
WBC count > 50,000/mm3 – pancreatic disease and pulmonary embolism 
Neutrophils predominate – suggests acute inflammation . It is seen in 
pneumonia , pancreatitis , pulmonary embolisation ,subphrenic abscess , 
early tuberculosis . 
Eosinophils predominate – indicates air or fluid in the pleural  space. It is 
seen in patients with spontaneous pneumothorax who undergone 
thoracotomy , introduction of air during thoracentesis into pleural space , 
traumatic hemothorax , pulmonary embolization , CABG , asbestos related 
effusion , drugs like dantrolene , bromocriptine , parasitic disease like 
amebiasis , ascariasis . 
Basophils  predominate – pneumothorax , pneumonia , leukemic pleural 
involvement . 
 Pleural fluid lymphocytosis  - malignancy , TB , CABG , leukemia or 
lymphomas . 
Mesothelial cells –  Tuberculosis in HIV patients . Whereas it is absent in 
complicated parapneumoniceffusions , malignancy after pleurodesis. 
3.Glucose levels : 
Glucose level < 60 mg / dL – malignancy ,parapneumonic 
effusions,rheumatoid disease , tuberculosis . Other causes include 
hemothorax , lupus pleuritis ,paragonimiasis , churg – strauss syndrome . 
4.Amylase level : 
It is elevated in pancreatic disease , malignancy , esophageal rupture . In 
later two cases the amylase is of salivary type. 
5.Lactate dehydrogenase level : 
LDH in the pleural fluid is a reliable indicator of degree of  inflammation of 
the pleura. More the inflamed surfaces , higher the LDH levels . The most 
common causes of elevated LDH levels are parapneumonic effusions and 
malignancy . These two conditions mostly meet the light’s criteria on the 
basis of levels of LDH than the protein levels .The isoenzymes elevated in 
these conditions are LDH – 4 and LDH – 5. They are thought to arise from 
the inflammatory WBC . 
  
Usually LDH isoenzyme is not used routinely . This is done in conditions 
where there is a bloody pleural fluid tap in a patient who is having 
transudative pleural effusion clinically .The pleural fluid protein meets the 
criteria for transudative pleural effusion but LDH levels meets the criteria for 
exudative pleural effusion. In these conditions isoenzyme LDH – 1 , 
confirms that the rise in LDH was due to blood . 
6.Pleural fluid pH : 
If the pleural fluid pH is less than 7.2 then we have to consider the following 
causes : complicated parapneumonic effusions , esophageal rupture , 
rheumatoid pleuritis , tuberculouspleuritis malignant pleural disease , 
hemothorax , systemic acidosis , lupus pleuritis , paragonimiasis , 
urinothorax . 
7.AdenosineDeaminase : 
ADA has two isoenzymes – ADA 1 and ADA 2 
ADA 1 is produced by lymphocytes , neutrophils , monocytes , macrophages 
ADA 2 is produced by macrophages and monocytes . 
 
 
 The cut off level for ADA level to diagnose tuberculous pleural effusion is  
40 to 45 U/L . The diagnosis of TB pleural effusion is more likely if the level 
is higher ie., more than 70 U/L .  
Other conditions with elevated ADA levels areempyema , rheumatoid 
pleuritis, neoplasms , Q fever , brucellosis . If the ADA 1 to ADA  ratio is 
less than 0.42 the diagnosis of TB pleuritis is increased .    
8.Interferon gamma : 
In patients with tuberculouspleuritis CD 4 lymphocytes  produce interferon 
gamma . It enhances the elimination of  intracellular parasites by increasing 
the production of polymyristate acetate induced hydrogen peroxide in 
macrophages. In monocytes this inhibits the mycobacterial growth . If the 
interferon gamma level is more than 200 pg / ml then the diagnosis of   
tuberculouspleuritis is made. 
9.Polymerase chain reaction : 
It is used in patients with low  numbers of tubercle bacilli  in pleural fluid . It 
is also used on pleural biopsy specimens . 
10. C – Reactive proteins more than 50 mg /L , high levels of lysozyme are 
also used to diagnose tuberculous pleuritis . 
 
  
10.Lipids : 
Chylothorax – Accumulation of chyle in the pleural space due to distruption 
of the thoracic duct. In these situations the triglyceride levels are increased . 
Chyliform pleural effusions – This is characterised by high levels of lecithin 
globulin levels . 
Pseudo chylous effusions – There is increased levels of cholesterols crystals . 
Triglyceride levels more than 110 mg / dL – Chylothorax is confirmed . But 
if the levels are less than 50 mg / dL then the patient is not having 
chylothorax . 
If triglyceride level is between 50 to 110 mg / dL then we need to perform a 
lipoprotein analysis .Chylothorax is diagnosed if there is presence of 
chylomicrons in the lipoprotein analysis of  pleural fluid. 
 
11.Bilirubin 
Bilirubin has a high molecular weight (584) .With respect to its 
concentration between serum and protein it behaves in a manner identical  to 
that of the high molecular weight proteins . Any serous membrane 
 inflammation often leads to increased capillary permeability and this enables 
the diffusion of high molecular weight bilirubin . 
 
A pleural fluid bilirubin of more than 0.48 mg / dL and a pleural fluid 
bilirubin to serum bilirubin ratio of more than 0.62 is considered as exudates. 
 
12.Cholesterol 
 The mechanism of  increased concentration of cholesterol in 
Exudative pleural effusion is not known clearly. 
The permeability of pleura is increased due to “serum leakage” and this leads 
to the accumulation of cholesterol in exudative pleural effusion . 
A pleural fluid cholesterol of more than 60 mg / dL is used in diagnosing 
exudates. 
 
 
 
 
 
 
 
 
  
RADIOGRAPHIC EXAMINATIONS  OF PLEURAL EFFUSIONS 
 
Typical Arrangement of Free Pleural Fluid 
In the pleural space the distribution of free fluid is influenced by two main 
factors.  
First, since the lung is less dense than pleural fluid, accumulation of the  
pleural fluid  occurs in the most dependent part of the thoracic cavity.  
The distribution of fluid within the free pleural space obeys the law of 
gravity. The lung also maintains its shape when compressed. Bearing, these 
2 factors in mind  it is easy to predict the distribution of excess pleural fluid.  
The fluid first gravitates to the base of the hemithorax and comes to rest 
between the inferior surface of the lung and the diaphragm, where the pleural 
sinus is the most inferior, particularly posteriorly. The fluid spills out into the 
costophrenic sinuses posteriorly, laterally, and anteriorly, when the fluid 
accumulation is higher. Additional fluid assumes a higher position in the 
thorax as it  spreads upward in a mantle-like manner around the convexity of 
the lung and gradually tapers .  
The lateral costophrenic angle is obliterated, in the posteroanterior 
projection.The density of the fluid is high laterally and curves gently 
medially and downward , to terminate at the mediastinum with a smooth,  
 
  
meniscus-shaped upper border. At the mediastinal border the layer of fluid is 
narrower than at the costal border.  
The upper surface of the pleural fluid density is semicircular in the lateral 
projection. It is high in the anterior and posterior regions. It curves smoothly 
downward to its lowest point approximately midway between the posterior 
chest walland the sternum . 
Frequently, in the lateral chest radiograph  a middle lobe step  is observed . 
The explanation for the middle lobe step is that the most dependent and the 
the first affected lobe is the lower lobe , the pleural fluid  starts to 
accumulates here. Therefore, it starts to float and shrink but maintains its 
shape. So the middle lobe is unaffected and its full volume is maintained . 
Accordingly, the result is a a middle lobe that retains its usual size and 
shrunken lower lobe . The fluid accumulation is mostly in the posterior part 
of the chest ,radiographically. The height of the pleural fluid is greater 
laterally , based on the radiologic appearance. When viewed en face ,this 
layer of fluid is of insufficient depth to cast a discernible shadow, so it 
assumes a meniscus shape. 
 
 
 
 
 Radiologic Signs 
The fluid first accumulates between the inferior surface of the lower lobe and 
the diaphragm, when the patient is in the upright position. The pleural fluid  
occupies this position , if the amount of fluid is small (approximately 75 mL) 
and without spilling into the costophrenic sinuses. The normal configuration 
of the diaphragm is maintained, with this small amount of fluid.  
 
The chest radiograph does not demonstrate that pleural fluid is present.  
When viewed in the lateral projection , accumulation of more fluid 
obliterates the costophrenic angle as it spills over into the posterior 
costophrenic angle  . The posterior costophrenic angle is normally sharp . It 
is obliterated by a homogeneous , shallow  shadow with a meniscus-shaped 
upper surface . There is also widening of the pleura that  lines the posterior 
thoracic wall . 
If  the posterior part of one or both diaphragms is obscured or the posterior 
costophrenic angle is obliterated, this indicates the presence of pleural fluid.  
Then we should be do further diagnostic tests . 
 
Moreover, the presence of clinically significant amounts of free pleural fluid 
can be nearly excluded , if both posterior costophrenic angles are clear and 
sharp. In the postero - anterior chest radiograph , lateral costophrenic angle is 
blunted with  increasing amounts of fluid . The entire outline of the 
 diaphragm is lost on the affected side, as more fluid accumulates . The fluid 
then extends upwards around the posterior , anterior and lateral thoracic 
walls. At the lung base , this fluid produces opacification which is the typical 
meniscus shape . 
 
Supine Position 
There are three characteristics that serve to differentiate the increased density 
due to parenchymal infiltrate from that due to a pleural fluid.  
First, in a properly exposed film , the vascular structures of the lung will be 
readily visible through the density, if the density is caused by pleural fluid. 
However, vascular structures are obliterated by the silhouette effect, if  a 
similar density is produced by any intrapulmonary process.•  
Secondly ,  the density is usually completely homogenous, if it is due to 
pleural fluid. Whereas, the infiltrates are usually less homogenous, if it is 
caused by an intrapulmonary processes.  
Third, the presence of air bronchograms . They are are present only if the 
increased density is due to a parenchymal infiltrate and not due to a pleural 
fluid. 
 
 
 
 
 Ultrasound 
In a patient with pleural effusion , the ultrasound can be used for the 
following purposes. They are 
 (a) to determine the presence of pleural fluid;  
(b) to identify an appropriate location for the attempted thoracentesis, chest 
tube placement, or pleural biopsy; 
 (c) to identify loculated pleural effusion;  
(d) to distinguish pleural thickening from  pleural fluid;  
(e) tosemiquantify the amount of pleural fluid;  
(f) to differentiate a lung abscess from a pyopneumothorax;  
(g) to assess a whether a pleurodesis is present; and  
(h) to evaluate the trauma patient for the presence of a  pneumothorax or a 
hemothorax. 
 
 
 
 
 
 
 
 
 
  
 
FIGURE 1 
ULTRASOUND OF LEFT LUNG AND SURROUNDING 
STRUCTURES  
 
 
 
 
 
 
 
 
  
FIGURE 2. 
ULTRASOUND OF RIGHT LUNG AND SURROUNDING 
STRUCTURES  
 
 
 
 
 
 
 
 
 
 FIGURE 3 
CHEST X RAY – POSTERIOR ANTERIOR VIEW SHOWING 
RIGHT SIDED PLEURAL EFFUSION . 
 
 
 
 
 FIGURE 4  
DIAGNOSTIC OR THERAPEUTIC THORACENTESIS  
-  RECOMMENDED POSITION OF THE PATIENT  
 
 
 
 FIGURE 5  
DIAGNOSTIC THORACENTESIS : THE PLEURAL SPACE IS 
ENTERED AND PLEURAL FLUID IS OBTAINED. 
 
 
 
 
  
FIGURE 6 
       CT CHEST PLAIN SHOWING PLEURAL EFFUSION 
 
 
 
 
 
 
 
  
 
SEPARATION OF TRANSUDATIVE FROM EXUDATIVE 
EFFUSIONS 
The accumulation of clinically detectable quantities of pleural fluid is 
distinctly abnormal.  
Indications of  diagnosticthoracentesis: 
1. Whenever the thickness of pleural fluid on ultrasound or the 
decubitus radiograph is greater than 10 mm or  
2. Whenever loculated pleural fluid is demonstrated with ultrasound  
3. Etiology of the effusion is unknown.  
A diagnostic thoracentesis when properly done takes less than 10 minutes.It 
should not cause any morbidity more than a venipuncture. In the 
management of the patient with pleural effusion , the information available 
from examination of the pleural fluid is invaluable. 
 
Transudative pleural effusion : 
If the systemic factors influencing the absorption or formation of pleural 
fluid are altered, transudative pleural effusion develops. 
The permeability of the capillaries to proteins,bilirubin,cholesterol is normal 
in the area where the fluid is formed.  
 
  
Examples of conditions producing transudative pleural effusions : 
1. Increased pulmonary interstitial fluid and a resulting pleural effusion - 
left ventricular failure . 
2.  Movement of fluid through the diaphragm from ascites due to cirrhosis . 
3. Decreased serum oncotic pressure with hypoproteinemia. 
 
Exudative pleural effusion  
In contrast, when the pleural surfaces or the capillaries in the location where 
the fluid originates are altered such that fluid accumulates , and an exudative 
pleural effusion develops.  
The common causes of exudative pleural effusions are : 
1.Pleural malignancy,  
2.Parapneumonic effusions, 
3.Tuberculosis  and 
4.Pulmonary embolism. 
In assessing a patient with a pleural effusion, the first question to ask  is 
whether that effusion is an exudates or a transudate. If the pleural effusion is 
a transudate, then no further diagnostic pleural procedures are necessary. 
Now therapy is directed to the underlying CHF, cirrhosis, or nephrotic 
syndrome.  
 Alternately, a more extensive diagnostic investigation is indicated , if the 
effusion proves to be an exudate,  to delineate the cause of the effusion. 
 
Total protein : 
Earlier to separate between transudate and exudates , a pleural fluid protein 
of 3gms was used. This test misclassified about 10% of pleural effusions.  
Light’s criteria: 
Light demonstrated the following criteria for diagnosing exudate. 
 Exudative pleural effusions meet at least one of the following criteria  
 Pleural fluid protein divided by serum protein greater than 0.5 
 Pleural fluid LDH divided by serum LDH greater than 0.6 
 Pleural fluid LDH greater than two thirds of the upper limit of normal 
serum LDH 
Other tests to differentiate exudates and transudate  
In recent years, following are the other tests for the separation of transudates 
from exudates. 
1.pleural fluid cholesterol >60mg,  
2.pleural fluid cholesterol>45mg,  
3.pleural fluid serum albumin gradient of <1.2, 
 4. pleural fluid protein gradient <3.1, 
5.pleural fluid serum bilirubin ratio >0.6  
When a pleural fluid shows above findings on analysis then it indicates it is 
an exudates.  
Light's criteria identify approximately 20% of transudative effusions as 
exudates. This mislabeling occurs most commonly in patients with CHF. 
When they are treated with diuretics before thoracentesis is performed. 
These mislabeled transudates barely meet the exudative criteria. 
The mislabeled transudate can be identified by examining the gradient 
between the serum and the pleural fluid protein levels. If this gradient is 
greater than 3.1 g/dL, one can presume that the fluid is actually a transudate. 
An albumin gradient of 1.2 g/dL rather than the protein gradient of 3.1 g/dL 
be used. However, the protein gradient is equally effective as the albumin 
gradient. Also the pleural fluid bilirubin and cholesterol can be used to 
correctly identify the transudates and exudates . 
And if the pleural fluid bilirubin is more than 0.48 mg/dl and pleural fluid to 
serum bilirubin ratio is more than 0.60 mg/dl , pleural fluid cholesterol more 
than 60 mg/dl then it is an exudates. 
 
 
  
 
Approach to diagnose a transudative or exudative pleural effusion  
To determine whether a pleural effusion is a transudate or an exudate , the 
following approach is recommended.  
First assess the fluid for Light's criteria. The fluid more likely an exudate if 
there is higher the value for the protein ratio, the LDH ratio, and the absolute 
value of the LDH. If the fluid meets the criteria for a transudative effusion, it 
is a transudate.  
If the fluid meets the criteria for an exudative effusion by only a small 
margin and the clinical picture is compatible with a transudative effusion, 
measure the protein gradient between the serum and pleural fluid . If this 
value is greater than 3.1 g/dL, then the fluid can be relabeled a transudate. 
And if the pleural fluid bilirubin is more than 0.48 mg/dl and pleural fluid to 
serum bilirubin ratio is more than 0.60, pleural fluid cholesterol more than60 
mg/dl then it is an exudates. 
 
 
 
  
Other Characteristics of Transudates 
Most transudates are clear, straw coloured, non - viscid, and odourless. The 
discovery of blood-tinged pleural fluid does not mean that the fluid is not a 
transudate.To give the pleural fluid a pinkish tinge , pleural fluid red blood 
cell (RBC) count should be more than 10,000/mm3 . Approximately 15% 
have RBC counts above this level. RBC ‘s contain a large amount of LDH . 
So elevated   LDH level in a blood-tinged or bloody transudative pleural 
effusion would  meet the criteria for an exudative pleural effusion. 
White blood cell (WBC) count  
White blood cell (WBC) count in the pleural fluid of most transudates is less 
than 1,000/mm3, but approximately 20% have WBC counts that exceed 
1,000/mm3. In transudative pleural effusions , WBC counts in pleural fluid 
above 10,000/mm3 are rare . The differential WBC count may be dominated 
by polymorphonuclear leukocytes, small lymphocytes, or other mononuclear 
cells in transudative pleural effusions.  
In a series of 51 transudative effusions, 7 (13%) had more than 50% 
polymorphonuclear leukocytes, whereas 17 (34%) had predominantly small 
lymphocytes, 23 (47%) had predominantly other mononuclear cells, and 
4(6%) had no single predominant cell type . 
 
 The glucose level in pleural fluid is similar to the serum glucose level, but 
the level of pleural fluid amylase is low. Because of active transport of 
bicarbonate from the blood into the pleural space ,there is always higher the 
pleural fluid pH in patients with transudative pleural effusions than the pH in 
simultaneously obtained blood . 
 
Diagnostic Thoracentesis : 
If the decubitus film demonstrates presence of free pleural fluid, then one 
should consider performing a diagnostic thoracentesis with the aid of 
ultrasound or with a CT scan. The thickness of the fluid is important in 
performing the diagnostic thoracentesis . If the thickness of the fluid on the 
decubitus radiograph, ultrasound, or the CT scan is less than 10 mm , then 
performing a diagnostic thoracentesis is difficult. However , we have to 
consider performing a diagnostic thoracentesis, if  the thickness of the fluid 
is greater than 10 mm.  
There is no need to perform diagnostic thoracentesis , if the patient has 
congestive heart failure. But in a patient with congestive heart failure if any 
of the following three conditions are met:  (a) the patient is febrile  (b) the 
effusions are not bilateral and comparably sized (c) the patient has pleuritic 
chest pain.  Otherwise, treatment of the congestive heart failure is initiated.  
A  diagnosticthoracentessis is done later, if the pleural effusions do not 
rapidly disappear. 
 To conclude the main aim of performing a diagnostic thoracentesis is 
determining  whether the patient has  an exudative or a transudative pleural 
effusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TRANSUDATIVE PLEURAL EFFUSIONS 
Alternation in the systemic factors influencing the formation and absorption 
of the pleural fluids leads to accumulation of the pleural fluid and formation 
of transudative pleural effusions . 
The major causes are : 
 
1.Congestive Heart Failure : 
The most common cause of pleural effusion is probably the congestive heart 
failure (CHF) .The researchers interested in pleural effusions usually do not 
see most patients with pleural effusions of  this  cardiac origin and this is the 
reason for the low incidence of pleural effusions secondary to heart failure in 
most of the studies  . The incidence of pleural effusions in patients with CHF 
is high. 
Pathophysiology : 
In the  concepts of pleural fluid formation and reabsorption in patients with 
heart failure , there are significant modifications in the  recent years. It was 
believed in the past that the accumulation of  the pleural fluid in patients 
with CHF was due to increased pressure in the parietal or the visceral pleural 
capillaries. According to Starling's equation, these increased pressures  
results in a decreased removal of fluid through the visceral pleura and an 
increased entry of fluid into the pleural space from the parietal pleura . 
 In patients with CHF , according to  current theories on pleural fluid 
formation and reabsorption, there is a  different entry pathway and a different 
exit pathway for pleural fluid. 
 It is believed that almost all fluid exits the pleural space through the 
lymphatics in the parietal pleura rather than by passively diffusing across the 
visceral pleura. In patients with CHF, accumulation of pleural fluid occurs 
when the rate of entry of fluid into the pleural space exceeds the capability of 
the lymphatics in the parietal pleura to remove the fluid . 
 
Clinical Manifestations : 
In patients with pleural effusions due to CHF they are usually associated 
with other manifestations of that disease. The patient has a history of 
increasing dyspnea on exertion,  orthopnea or paroxysmal nocturnal dyspnea 
, increasing peripheral edema. The dyspnea is frequently out of proportion to 
the size of the effusion.  
 
Physical examination : 
Physical examination usually reveals signs of the pleural effusions as well as 
signs of both left-sided heart failure with an S3 ventricular gallop and rales 
and right-sided heart failure with peripheral edema and distended neck veins. 
 
 
 Investigations : 
The chest radiograph almost always reveals usually bilateral pleural 
effusions and cardiomegaly. The most common cause of bilateral pleural 
effusions is congestive heart failure . But only 88% of the patients studied 
had bilateral pleural effusions ,if cardiomegaly is not present. 
 
The mean volume of pleural fluid in the right pleural space (1,084 mL) when 
compared to the mean volume of pleural fluid in the left pleural space  
(913 mL),was only slightly greater. Also mediastinal lymphadenopathy is 
common in patients with pleural effusions that are secondary to CHF.  
 
Diagnosis : 
If the patient has  bilateral pleural effusions and cardiomegaly,  not febrile, 
and no history of pleuritic chest pain, we have to first initiate treatment of the 
CHF. Then we have to observe the patient and determine whether the pleural 
fluid is reabsorbed. We then perform a diagnostic thoracentesis , if the 
effusions do not disappear within a few day.  
One problem with this approach is that the characteristics of the pleural fluid 
may change from those of a transudate to those of an exudates , since the 
patients are with diuresis.  
 
 
  
Serum pleural fluid albumin or protein gradient : 
The serum to pleural fluid protein gradient should be examined , if the 
pleural fluid meets exudative criteria but the effusion is thought to be due to 
CHF. If this gradient is greater than 3.1 g/dL, additional diagnostic studies 
are not indicated because the pleural effusion is probably due to the CHF . 
Currently, as the protein gradient is already available when Light's criteria 
are measured , the protein gradient of 3.1 g/dL is preferred to the albumin 
gradient.  
 
Pro-brain natriuretic peptide : 
The measurement of the serum or pleural fluid pro-brain natriuretic peptide 
(pro-BNP) , is an another test that should be considered for establishing the 
diagnosis of CHF. The level NT pro-brain natriuretic peptide (NT pro-BNP) 
considereddiagnostic of CHF is 1500pg/mL 
Treatment 
In a patient with pleural effusion secondary to heart failure the preferred 
treatment is to treat the heart failure with the following drugs., 
- digitalis, 
- diuretics – to reduce preload , and  
- dilators - to reduce afterload .  
 The pleural effusion disappears , if we manage heart failure successfully. In 
most patients with heart failure , the pleural effusion is effectively managed 
only with above management . 
Occasionally, the patients tends to be very dyspneic, if they are associated 
with large pleural effusions. Such persons may get rapid relief from the 
dyspnea , if about 0.5L to 1.0L of pleural fluid are removed . Sometimes 
therapeutic thoracentesis is indicated in patients with heart failure and large 
pleural effusions that are refractory to treatment, to get symptomatic relief . 
So consider interventions to control the pleural effusions , in such patients. 
 
2. Hepatic Hydrothorax 
One of the complication of hepatic cirrhosis is pleural effusion. But only 
when ascitic fluid is present, pleural effusions usually occur. They are 
usually called as hepatic hydrothorax. 
Pathophysiology 
It is evident from the foregoing studies, that the orgin of pleural fluid in 
these patients is from the ascitic fluid.  
The fluid in the peritoneal cavity passes directly through the defects in the 
diaphragm to the pleural space . The diaphragm may be stretched in  patients 
with tense ascites, causing microscopic defects. This is because of the 
increased intraabdominal pressure.  There is always a one-way transfer of 
 fluid from the peritoneal to the pleural cavity ,in patients with ascites. The is 
because of increased hydrostatic pressure in the asciticfluid . 
In some patients, the lymphatic vessels play an important role in the 
production of the pleural effusion. The mechanism behind this is the transfer 
of ascitic fluid across the diaphragm by the lymphatic vessels . 
To conclude , the dominant mechanism of hepatic hydrothorax is the direct 
movement of fluid across the diaphragm. Because the placement of the chest 
tube results in diminution in the amount of ascites, within minutes. 
 
Clinical Manifestations 
The clinical pictures of  cirrhosis and ascites dominate in patients with 
pleural effusions secondary to cirrhosis. At times, in association with large 
pleural effusions , these patients develop acute dyspnea. Although the pleural 
effusions may be small to moderate in size, they are frequently large and 
occupy the entire hemithorax. The diaphragmatic defect permits fluid to flow 
into the pleural cavity  from the peritoneal cavity , until the pleural pressure 
approaches the peritoneal pressure and this results in development of  large 
pleural effusion. 
Diagnosis 
It is usually easy to diagnose the pleural effusion that is secondary to 
cirrhosis with ascites. We should  perform both a paracentesis and a 
thoracentesis. This is to confirm that the ascites and pleural fluid are  
 compatible with the diagnosis. Also to ascertain that they are not have high 
polymorphonuclear cell counts.  
The pleural fluid is occasionally blood tinged or is frankly bloody. But  due 
to the poor coagulation status of the patient , such findings have no 
significance. The differential cell count is dominated by  polymorphonuclear 
leukocytes, small lymphocytes, or other mononuclear cells.  
To rule out pancreatic ascites amylase levels should be determined. Also a 
cytologic examination should be performed to rule out malignant disease. 
This should be done in both pleural fluid and ascitic fluid. 
 
Treatment 
Since  the hydrothorax is an extension of the peritoneal fluid in patients with 
cirrhosis and ascites , the management of pleural effusions always should be 
directed toward treatment of the ascites .  
The patient should be put on a low-salt diet, and moderate fluid restriction. 
Then diuretics should be administered. The combination of furosemide and 
spironolactone , is the best diuretic therapy. The initial starting dose is 40 mg 
of furosemide and 100 mg of spironolactone and they can be titrated upto a 
maximum dose of 160 mg of furosemide and 400 mg of spironolactone. This 
combination appears to have the optimal ratio for the two diuretics. 
 
 
 3. Nephrotic Syndrome 
The nephrotic syndrome is common in patients with the pleural effusion. 
 
Mechanism of pleural fluid accumulation : 
The combination of increased hydrostatic pressure and decreased plasma 
oncotic pressure , is the mechanism responsible for the transudative pleural 
effusion in patients associated with the nephrotic syndrome.  
 
Diagnosis : 
In the typical clinical situation to diagnose pleural effusion secondary to the 
nephrotic syndrome it is not difficult. But  to confirm that the pleural fluid is 
indeed a transudate ,a diagnostic thoracentesis should be performed.  
In patients with the pleural effusion and nephrotic syndrome, the possibility 
of pulmonary embolism should always be considered. In all patients with the 
pleural effusion and nephroticsyndrome , one should always obtain a lung 
scan or a CT angiogram. It is important that evidence of deep venous 
thrombosis should be sought with venograms, pulmonary arteriogram or a 
impedance plethysmograms, if the lung scan or spiral CT scan is equivocal.  
 
 
 
 
 Treatment : 
The main aim of  treatment is  to decrease the protein loss in the urine of 
patients with pleural effusion and associated with the nephrotic syndrome. 
This is done  to decrease the increased extracellular volume and to increase 
the plasma protein.  
This is best accomplished by administering  
- diuretics in conjunction with a low-sodium diet,  
- angiotensin-converting enzyme inhibitors.  
As serial therapeutic thoracentesesonly  deplete the protein stores, they 
should not be performed . We should consider a pleurodesis with a 
sclerosingagent , in selected patients who are symptomatic from the pleural 
effusion. 
 
 
 
 
 
 
 
 
  
EXUDATIVE PLEURAL EFFUSION  
MOST COMMON CAUSES ARE : 
1. Parapneumonic pleural effusion 
2. Pleural effusion related  to metastatic malignancies 
3. Tuberculous pleural effusion 
1.METASTAIC MALIGNANCIES AND PLEURAL EFFUSION : 
 The exudative pleural effusion secondary to malignant disease 
involving the pleura is the second leading cause of  exudative pleural 
effusion. Parapneumonic effusion ranks first in this category. 
Common carcinomas associated with malignant pleural effusions are : 
1. Lung carcinoma , 
2.  Breast carcinoma , 
3.  Lymphoma , 
4.  Ovarian carcinoma , 
5.  Sarcoma 
Rarely carcinoma of uterus , cervix , stomach , colon , pancreas , bladder  
 
  
MECHANISMS BY WHICH MALIGNANT DISEASE LEADS TO 
PLEURAL  EFFUSION 
There are two types of mechanisms by which the malignant disease  leads to 
the development of pleural effusions 
1.Direct mechanism : 
a) Increased permeability due to pleural metastasis 
b) Obstruction of the pleural lymphatic vessels caused by pleural 
metastasis 
c) Decreased pleural lymphatic drainage and mediastinal node 
involvement 
d) Chylothorax – thoracic duct interruption 
e) Decreased pleual pressure – bronchial obstruction 
f) Due to involvement of pericardium 
2.Indirect result : 
a) Pulmonary embolism 
b) Postobstructive pneumonitis  
c) Hypoproteinemia 
d) Postradiation therapy 
 
 CLINICAL MANIFESTATIONS : 
The most common symptom in patients with malignant pleural effusion is 
dyspnea . Also the symptoms due to the underlying disease will 
predominate. The symptoms due to underlying malignancy are weight loss , 
malaise , anorexia .  
The other manifestations are  chest pain , hemoptysis, cough in patients with 
lung malignancy , breast mass in carcinoma breast , swelling in neck, axilla 
inguinal regions with mass in the abdomen in case lymphomas . 
Chest radiograph : 
Besides the pleural effusion , pulmonary abnormalities are demonstrated by  
the patients with pleural effusion secondary to carcinomas. Also there is 
involvement of mediastinallymphadenopathy . 
The pulmonary abnormalities are : 
a) pleural nodularity ,  
b) pleural rind ,  
c) mediastinal pleura involvement ,  
d) pleural thickening > 1 cm  
 
 
 Pleural fluid analysis : 
- Grossly bloody with RBC count > 100,000/mm3 . 
- WBC count between 1,000 to 10,000 / mm3 with lymphocytes 45 % , 
other mononuclear cells > 40% , polymorphonuclear cells  15 % . 
- Reduced pleural fluid glucose level less than 60 mg/ dl . 
- Pleural fluid pH below 7.3 . 
- Cytology : it is used to classify the histological  subtype like 
adenocarcinoma but not the primary site of tumour. 
- Immunohistochemicaltests :carcinoembryonic antigen stained by 
metastatic adenocarcinoma and also stains MOC 3,1,B72.3,Ber – EP4 
and BG – 8. Malignant mesothelial cells stain positive for cytokeratin 
and calretin . 
- Tumormarkers :carcinoembyronic antigen (CEA), carbohydrate 
antigen (CA) 15 – 3, 19 – 9 , 549 and 72.Neuron specific enolase 
,SCC antigen , SSEA – sialyl state specific mouse embryonic antigen , 
cytokeratin 19 fragments  . 
Non invasive test : 
This includes measurement of oncogenes, lectin binding, FISH,                 
flow cytometry, proteomics , chromosomal analysis and hyaluronic acid. 
 But the only test that is advised is flow cytometry . This is done when a 
lymphoma is suspected . The diagnosis of lymphoma is done by showing the 
clonality of lymphocytes in pleural fluid . 
Pleural biopsy – CT guided or via thoracoscopy 
TREATMENT : 
In the management of pleural effusion due to metastatic disease the 
important thing is to identify the site of primary. This is because to decide 
whether the primary tumor responds to systemic chemotherapy or not. 
Because some tumors like breast carcinoma , lymphoma , small cell 
carcinoma can responds to systemic chemotherapy very well. 
Also intrapleural chemotherapy with cisplatin , staphylococcal aureus super 
antigen ( SSAg ) , rituximab , interferon – gamma ,tumor necrosis factor , 
interleukin IL -2 has been tried with varying results. 
In patients with malignant pleural effusion and a chylothorax , malignancy 
usually involves the  thoracic duct . So in these patients it is good to 
administer radiotherapy to the mediastinum. 
We have to consider removal of the pleural fluid , if the tumor is not 
responding to chemotherapy or fails to respond to treatment . This is done 
mainly to relieve the dyspnea. 
 
 The procedures available for the treatment resistant pleural effusion are ; 
1. Indwelling pleural catheter  ( pleur X ) 
2. Pleurodesis 
3. Intercostal drainage 
4. Pleuroperitoneal shunt  
5. Repeated thoracentesis 
6. Pleurectomy 
2.TUBERCULOUS PLEURAL EFFUSION  
The development of pleural effusion in a patient with absence of 
radiologically apparent TB  indicates that it would be a sequelae to the 
primary infection that occurred    6 to 12 weeks before  or it may be due to 
reactivation of  TB . 
Pathogenesis  oftuberculous pleural effusion : 
In tuberculous patients there are subpleuralcaseous focus. Tuberculous 
pleural effusion occurs due to  rupture of the subpleuralcaseous focus in the 
lung to the pleural space. 
In the development of tuberculous pleural effusion the delayed 
hypersensitivity plays a major role .There is clonal expansion of  
lymphocytes sensitised  to the tuberculous protein . Initially the macrophages 
 predominate in the pleural fluid from day 2 to day 6 and then the 
lymphocytes predominate in the pleural fluid. 
It is clear that the delated hypersensitivity increases the pleural capillaries 
permeability to protein. There is higher rate of pleural fluid formation due to 
the increased levels  of pleural fluid protein. Also there is increased levels of 
VEGF, which also increases the permeability. This leads to the accumulation 
of pleural fluid and development of pleural effusion . 
Also there is decrease in the clearance of proteins in the pleural space. This 
is because of the impedence to the clearance of proteins by the lymphatics as 
a result of delayed hypersensitivity reactions . 
Clinical manifestation : 
Patients with pleural TB have symptoms such as fever, dry cough ,pleuritic 
chest pain, and dyspnea.  
Physical findings are those of pleural effusion such as dullness to percussion 
and absence of breath sounds. 
In HIV individuals there will be longer duration of illness. The incidence of 
chest pain is low , but night sweats , fatigue , diarrhoea , hepatomegaly , 
lymphadenopathy , splenomegaly  are more common.  
They have associated parenchymal lesions , smear for acid fast bacilli 
positive and also culture positive for AFB. 
 DIAGNOSIS : 
Tuberculin skin testing :Tuberculin skin testing  is almost always positive 
if performed after 8 weeks of development of symptoms . So a negative skin 
testing after 8 weeks of development of symptoms can be used to rule out 
TB. However in malnourished individuals or HIV patients the test remains 
negative . 
 
Pleural fluid analysis : 
1. Pleural fluid protein elevated and usually above 5 g/dL 
2. WBC count has more than 50% small lymphocytes . If there is 
eosinophils it suggests previous thoracentesis or associated 
pneumothorax . 
3. Mesothelial cells not more than 5 % . 
4. Adenosine deaminase levels more than 70 U/L 
5. Interferon gamma levels more than 3.7IU/ml 
6. Low pleural fluid pH and CRP levels more than 30 mg/dl 
7. Pleual biopsy – demonstration of  parietal pleura granuloma , AFB 
, caseous necrosis. 
8. Pleual fluid AFB staining and culture for mycobacteria 
 
  
3.Parapneumonic effusion : 
When any pleural effusion is associated with bacterial pneumonia , lung 
abscess or bronchiectasis , it is called as parapneumonic effusion . 
An empyema is defined as pus in the pleural space. Many complicated 
parapneumonic effusions are empyema . 
According to Weese et al. empyema is charecterised by specific gravity 
greater than 1.018 , protein more than 2.5 g/dL , WBC count  more than 500 
cells/ mm3 But according to Vianna empyema is defined as pleural fluid 
protein more than 3.0 g/dL , WBC greater than 15000 / mm3 or positive 
bacterial cultures. 
Pathogenesis : 
1.Exudative stage : 
 This stage is characterised by rapid accumulation  of sterile pleural 
fluid in pleural space. The fluid orginates from the interstitial spaces of lung 
and also from the visceral pleural capillaries due to increased capillary 
permeability. There is low WBC count , low LDH level and a normal 
glucose level in the pleural fluid at this stage. This stage resolves if  
appropriate antibiotics is instituted. 
  
2.Fibropurulent stage 
 The pleural space is invaded by the bacteria , if antibiotics are not 
intiated.  In this stage there is accumulation of large amounts of pleural 
fluids which is rich in bacteria ,polymorphonuclear leucocytes  and cellular 
debris . The visceral and parietal pleura are covered by a continuos sheet of 
fibrin. This leads to the formation of loculation and prevents the spread of 
pus . But this makes the insertion of chest tube difficult. In this stage there is 
higher pleural fluid LDH and lower pleural fluid glucose and pH 
3.Organisation stage 
This stage is characterised by pleural peel. The fibroblasts grow in to the 
exudates and an inelastic membrane is produced . The lung is encased by this 
inelastic pleural peel and makes it functionless. The exudates is thick at this 
stage and it may spontaneously drain through the chest wall called as 
empyema necessitatis or into the lung producing a bronchopleuralfistula . 
The most common organisms are Staphylococcal aureus , Escherichia coli  
and anaerobe Bacteroids . 
 
 
 Clinical features : 
 Fever , cough with expectoration , chest pain are the major symptoms 
.In immunocomprimised person fever may be absent . If the fever is present 
for more than 48 hours after the institution of antibiotics then it is called as 
parapneumonic effusion. The history of alcoholism , seizures or an episode 
of unconsciousness should be sought as it leads to aspiration. 
Light’s classification for parapneumonic effusions and empyema : 
1.Nonsignificant pleural effusion 
2.Typicalparapneumonic pleural effusion 
3.Borderline complicated pleural effusion 
4.Simple complicated pleural effusion 
5.Complex complicated pleural effusion 
6.Simple empyema 
7.Complex empyema 
Diagnosis : 
1. During thoracocentesis , there is frank pus . 
2. The pleural fluid  will be positive for  Gram stain , culture.  
 3. Pleural fluid glucose less than 40 mg / dL , pH < 7.0 , LDH > 3 times 
the upper limit. 
Also the above findings along with loculations constitutes the bad prognostic 
factors for both empyema and parapneumonic effusions. 
Management : 
Antibiotics : 
Community acquired pneumonias : 
- Fluroquinolones such as levofloxacin , moxifloxacin ,gatifloxacin 
or a macrolide such as azithromycin , clarithromycin plus a beta 
lactams such as cefotaxime , ceftriaxone , ampicillin – sulbactam . 
- If pseudomonas is suspected anti pseudomonas antibiotics like 
meropenam ,imipenam , piperacillintazobactam or cefepime is 
used. 
Anaerobes – metronidazole or clindamycin ., 
MRSA – vancommycin 
Management for pleural effusions : 
1.Therapeuticthoracentesis 
2.Tubethoracostomy 
 3.Intrapleuralfibrinolytics like streptokinase , streptodornase , tissue 
plasminogen activator 
4.Video assisted thoracoscopy with lysis of adhesions and / or decortications 
5.Decortication 
6.Open drinage 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
STUDY POPULATION: 
This study is to be conducted among 50 patients with pleural Effusion , 
attending the Department of  Medicine & Department of  Thoracic Medicine 
in Govt. Rajaji Hospital, Madurai. 
Inclusion criteria: 
 In Patients with clinical and radiological evidence of pleural effusion 
irrespective of etiology,  both sex 
 Age > 12 years 
Exclusion criteria: 
 Patients having jaundice , dyslipidemia , hypoproteinemia 
 Age < 12 years 
 
ANTICIPATED OUTCOME: 
 Total Pleural fluid Bilirubin and ratio to serum levels, Pleural fluid 
Cholesterol and Pleural fluid Total Protein level is superior or 
supportive to Light’s criteria in differentiating transudates and 
exudates. 
 
  
DATA COLLECTION: 
•     A Brief history with clinical examination will be done. 
• Detailed Clinical Examination , 
• Pleural fluid bilirubin , Serum Bilirubin , Pleural fluid cholesterol, 
Pleural fluid total protein, Serum total protein  ,  Pleural & Serum 
LDH  are estimated. 
LABORATORY INVESTIGATIONS: 
1. Pleural fluid bilirubin & Serum Bilirubin 
2. Pleural fluid cholesterol  
3. Pleural fluid total protein & Serum Protein  
4. Pleural fluid LDH & Serum LDH 
 
STUDY PROTOCOL: 
 Patients with clinical and radiological evidence of pleural effusion 
are to be included in the study. 
 Then  they are classified in to exudates and transudates on the basis 
of the clinical , radiological and biochemical evaluation . 
  In all the patients following investigation are done to classify them 
as exudates and transudates 
 Pleural fluid bilirubin & Serum Bilirubin , Pleural fluid cholesterol, 
Pleural fluid total protein are estimated and the patients are 
classified in to exudates and transudates. 
 Then the patients are classified in to exudates and transudates on 
the basis of Light’s criteria. 
 Now the classification of exudates and transudates done on the 
basis of Total Pleural fluid bilirubin and its ratio to serum  
bilirubin  , Pleural fluid cholesterol , Pleural fluid Total protein are 
compared with results of the classification of exudates and 
transudates done on the basis of  Light’s criteria. 
 Sensitivity , specificity , Positive predictive value , negative 
predictive value ,  diagnostic accuracy of each testsare calculated . 
 
DESIGN OF STUDY: 
Prospective analytical study 
PERIOD  OF STUDY: 
JANUARY 2014 TO AUGUST 2014 
 
  
CONSENT:  
Individual  written and informed consent. 
ANALYSIS: 
SIMPLE STATISTICAL ANALYSIS 
CONFLICT OF INTEREST : 
NIL 
FINANCIAL SUPPORT:   
NIL 
 
 
 
 
 
 
 
 
           RESULTS 
             Table 1 : Age distribution of the study population (n=50) 
Age group Frequency Percent 
 
<25 years 
 
2 
 
4 
 
26 – 40 years 
 
6 
 
12 
 
41 – 55 years 
 
17 
 
34 
 
56– 70 years 
 
24 
 
48 
 
>70 years 
 
1 
 
2 
 
Total 
 
50 
 
100 
 
Mean age (± S.D): 53.3 (11.65) years, minimum : 21 years,              
maximum : 75 years. 
Comments: About 48% of the study subjects were in the age group of 56-70 
years while the 34% were in the age group 41-55 years. 
 
 
 
 
              FIGURE 7 
AGE DISTRIBUTION OF THE STUDY POPULATION 
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Table 2 : Gender distribution of the study population (n=50) 
 
Gender 
 
Frequency 
 
Percent 
 
Female 
 
21 
 
42 
 
Male 
 
29 
 
58 
 
Total 
 
50 
 
100.0 
 
Comments: About 58 % of the study subjects were males while the 
remaining 42% were females. 
 
 
 
 
 
 
  
FIGURE 8 
GENDER DISTRIBUTION OF THE STUDY POPULATION 
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Table 3 : Clinical criteria for classifying pleural effusions as exudates 
and transudates 
 
   Diagnosis  
  
                                  Criteria 
 
 
 
Tuberculosis 
 
Clinically cough , fever with evening rise of temperature, 
loss of weight and appetite  
sputum showing  AFB,  
ADA in pleural fluid , 
Chest x ray showing pleural effusion , 
Response to ATT. 
 
 
Parapneumonic   
effusions 
 
Clinically cough with expectoration, fever with chills & 
rigors,  
Chest x ray showing pleural effusion,  
Bacteria in pleural fluid/sputum. 
 
Malignant 
pleural 
effusions 
 
Pleural fluid cytology,  
Pleural biopsy, 
Demonstration of primary sites. 
 
 
Congestive 
cardiac failure 
 
Clinically pedal edema , ascites, elevated JVP  , basal 
crepitations,  
Chest x ray , ECG, Echocardiography, Response to 
Diuretics 
 
 
Chronic liver      
disaese 
 
 
Signs of Liver cell failure  , ascites ,  splenomegaly , 
 
Chronic kidney 
disease 
 
Raised serum urea and creatinine, 
Contracted kidneys in ultrasonogram , along with signs 
and symptoms of volume overload. 
 
  
Table 4 : Classification of the study population according to clinical 
criteria 
 
Clinical classification 
 
Frequency 
 
Percent 
 
Exudates 
 
28 
 
56 
 
Transudates 
 
22 
 
44 
 
Total 
 
50 
 
100 
 
Comments: About 56% of the study subjects are exudates while 44%  are  
transudates . 
 
  
 
 
 
 FIGURE 9 
CLASSIFICATION OF THE STUDY POPULATION 
ACCORDING TO CLINICAL CRITERIA 
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 Table 5: Distribution of Exudates in the study group 
 
Etiology 
 
Frequency 
 
Percent 
 
Tuberculosis 
 
14 
 
50 
 
Malignant pleural 
effusions 
 
10 
 
35.72 
 
Parapneumonic 
effusions 
 
4 
 
14.28 
 
Total 
 
28 
 
100 
 
Comments : About 50 % of study group have tuberculosis , 35.72 % have 
malignancy and 14.28 % have parapneumonic effusions. 
 
 
 
 
 
 
 
 Table 6 : Distribution of Transudates in the study group 
 
Etiology 
 
Frequency 
 
Percent 
 
Congestive cardiac 
failure 
 
10 
 
45.46 
 
Chronic liver disease 
 
8 
 
36.36 
 
Chronic kidney 
disease 
 
4 
 
18.18 
 
Total 
 
22 
 
100 
 
Comments : About 45.46 % of study group have congestive cardiac failure , 
36.36 % have chronic liver disease and 18.18 % have chronic kidney disease. 
 
 
 
 
 
 
 Table 7: Descriptive statistics of pleural fluid  protein , serum and 
pleural fluid bilirubin and pleural fluid cholesterol levels of the 
study population (n=50) 
 
Comments: 
1) The mean level of protein and cholesterol  in pleural fluid is 3.04 
gm/dl and 49.98 mg/dl . 
2) The mean level of bilirubin in serum and pleural fluid is 0.61 mg/dl 
and   0.43 mg/dl . 
 
 
Descriptive          
statistics 
Pleural 
Fluid 
Protein 
(gm/dl) 
Pleural 
Fluid  
Bilirubin  
(mg/dl) 
Serum  
Fluid  
Bilirubin  
(mg/dl) 
Pleural 
Fluid 
Cholesterol 
(mg/dl)  
Mean 3.04 0.43 0.61 49.98 
Standard 
Deviation 0.53 0.121 0.14 19.69 
Minimum 2.10 0.20 0.32 16.00 
Maximum 4.40 0.61 0.90 80 
 Table 8 : Identififcation of  exudates by various criteria (n=28) 
Criteria Correctly classified as 
exudate N (%) 
Wrongly classified as   
transudate 
N (%) 
 
Light ‘s criteria 
 
24 (85.72%) 
 
4 (14.28%) 
 
Pleural fluid Bilirubin 
 
23 (82.14%) 
 
5 (17.86%) 
 
Pleural fluid  / Serum 
Bilirubin ratio 
 
27 (96.42%) 
 
1 (3.58%) 
 
Pleural fluid 
cholesterol 
 
21 (75.00%) 
 
7 (25.00%) 
 
Pleural fluid Total 
Protein 
 
26 (92.85%) 
 
2 (7.15%) 
 
Comments: 
 1) According to the Lights criteria, 85.72 % of the cases were detected 
with exudative  pleural effusion. 
 2) According to Pleural fluid Bilirubin, 82.14 % of the cases were 
detected with exudative pleural effusion. 
 3) According to Pleural fluid  / Serum Bilirubin ratio, 96.42 % of the 
cases were detected with exudative pleural effusion. 
 4) According to Pleural fluid cholesterol, 75% of the cases were 
detected with exudative pleural effusion 
5) According to Pleural fluid Total Protein, 92.85% of the cases were 
detected with exudative pleural effusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 9 :Identififcation  of  transudate by various criteria (n=22) 
Criteria 
Correctly classified as 
transudate 
N (%) 
Wrongly classified as 
exudate 
N (%) 
 
Light ‘s criteria 
 
20 (90.90%) 
 
2 (9.10%) 
 
Pleural fluid Bilirubin 
 
19 (86.36%) 
 
3 (13.64%) 
 
Pleural fluid  / Serum 
Bilirubin ratio 
 
 
20 (90.90%) 
 
 
2 (9.10%) 
 
Pleural fluid 
cholesterol 
 
19 (86.36%) 
 
3 (13.64%) 
 
Pleural fluid Total 
Protein 
 
21 (95.45%) 
 
1 (4.55%) 
 
Comments: 
 1) According to the Lights criteria, 90.90 % of the cases were detected 
with transudative  pleural effusion. 
 2) According to Pleural fluid Bilirubin, 86.36 % of the cases were 
detected with transudative pleural effusion. 
 3) According to Pleural fluid  / Serum Bilirubin ratio, 90.90 % of the 
cases were detected with transudative pleural effusion. 
 4) According to Pleural fluid cholesterol, 86.36 % of the cases were 
detected with transudative pleural effusion 
5) According to Pleural fluid Total Protein, 95.45 % of the cases were 
detected with transudative  pleural effusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Table 10 :Distribution of exudates in study population (n=28) 
 
 
 
Criteria 
 
 
Tuberculosis 
 
 
Para 
pneumonic 
effusions 
 
 
Malignant 
pleural 
effussion 
 
 
  P 
value 
 
Light ‘s 
criteria 
Exudate  
12 
 
9 
 
3 
 
 
   0.003 
Transudate   
2 
 
1 
 
1 
 
Pleural 
Fluid 
bilirubin 
Exudate 
>0.48 
mg/dL 
 
13 
 
7 
 
3 
 
 
 
   0.009 Transudate 
<0.48 
mg/dL 
 
 
1 
 
3 
 
1 
 
Pleural      
Fluid 
Serum 
Bilirubin 
Exudate 
> 0.62 
 
 
13 
 
10 
 
4 
 
 
<0.001 
Transudate 
< 0.62 
 
1 
 
0 
 
0 
 
Pleural 
Fluid 
Cholesterol 
Exudate 
> 60 mg/dL 
 
 
10 
 
8 
 
3 
 
 
  0.050 
Transudate 
< 60 mg/dL 
 
4 
 
2 
 
1 
 
Pleural 
Fluid 
Total 
Protein 
Exudate 
> 3 g/dL 
 
14 
 
9 
 
3 
 
 
<0.001 
Transudate 
< 3.0g/dL 
 
 
0 
 
1 
 
1 
 
  
FIGURE 10 
IDENTIFIFCATION OF EXUDATE  BY VARIOUS CRITERIA 
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Table 11 :Distribution of transudates in study population (n=22) 
 
 
 
Criteria 
 
 
Congestive 
Cardiac 
Failure 
 
 
Chronic 
Liver 
Disease 
 
 
Chronic 
Kidney 
Disease 
 
 
  P 
value 
 
Light ‘s 
criteria 
Transudate  
8 
 
8 
 
4 
 
 
0.003 
Exudate  
2 
 
0 
 
 
0 
 
Pleural 
Fluid 
bilirubin 
Transudate 
< 0.48 
    mg/dL 
 
8 
 
8 
 
3 
 
 
0.009 
Exudate 
> 0.48 
mg/dL 
 
2 
 
0 
 
1 
 
Pleural 
Fluid  
Serum 
Bilirubin 
Transudate 
< 0.62 
 
10 
 
8 
 
2 
 
 
0.003 
Exudate 
> 0.62 
 
0 
 
0 
 
2 
 
Pleural 
Fluid 
Cholesterol 
Transudate 
< 60 mg/dL 
 
9 
 
6 
 
4 
 
 
0.009 
Exudate 
> 60 mg/dL 
 
1 
 
2 
 
0 
 
Pleural 
Fluid Total 
Protein 
Transudate 
< 3.0g/dL 
 
10 
 
7 
 
4 
 
 
<0.001 
Exudate 
> 3 g/dL 
 
0 
 
1 
 
0 
 
  
FIGURE 11 
IDENTIFIFCATION  OF TRANSUDATE BY VARIOUS CRITERIA  
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 Table 12 : Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) , diagnostic accuracy of various criteria. 
 
 
Criteria  
 
 
Sensitivity  
 
 
Specificity  
 
Positive 
predictive 
value 
 
Negative 
predictive 
value 
 
Diagnostic 
accuracy  
 
Light ‘s 
criteria 
 
 
85.71 % 
 
 
 
90.90% 
 
 
92.30% 
 
 
83.33% 
 
 
88% 
 
Pleural 
Fluid 
bilirubin 
 
 
82.14 % 
 
 
86.36% 
 
 
88.46% 
 
 
79.16% 
 
 
84% 
 
Pleural 
Fluid/ 
Serum 
Bilirubin 
 
 
96.42% 
 
 
90.90% 
 
 
93.10% 
 
 
95.23% 
 
 
94% 
 
 
 
 
Pleural 
Fluid 
Cholesterol 
 
 
75.00% 
 
 
86.36% 
 
 
87.50% 
 
 
73.07% 
 
 
80% 
 
Pleural 
Fluid Total 
Protein 
 
 
92.85% 
 
 
95.45% 
 
 
96.29% 
 
 
95.23% 
 
 
94% 
 
 
 Comment : 
The misclassification of exudates and transudates by various criteria when 
compared to Light’s criteria is not statistically significant as p value is <0.05. 
 
To classify an exudative pleural effusion from a transudative pleural 
effusion, the most specific test is pleural fluid total protein and the most 
sensitive test is pleural fluid / serum bilirubin ratio .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
DISCUSSION  
 
 One of the most common disease entity encountered by physicians 
worldwide is pleural effusion . In a situation where undiagnosed pleural 
effusion has come upon, the first and foremost thing to be resolved is 
whether the fluid is a transudate or exudate. The most frequently used Light's 
criteria, though still considered as a gold standard, often misclassify a 
transudate as an exudates. The present study was undertaken to evaluate the 
efficacy of pleural fluid bilirubin and its ratio to serum levels  , pleural fluid 
cholesterol and pleural fluid total protein in distinguishing pleural fluid 
transudates and exudates and its correlation with Light’s criteria .  
 
Method of study: 
This study was conducted in Govt. Rajaji Hospital, Madurai which is 
affiliated to Madurai Medical College. This study subjects were selected 
from the patients admitted in Department of Medicine and Department of 
Medicine , Govt. Rajaji Hospital. 
The study was conducted in 50 patients; the patients had pleural effusion 
with clinical background of congestive cardiac failure, chronic liver disease , 
chronic kidney disease ,tuberculosis , parapneumonic effusions , malignancy. 
 The patients are examined clinically with the following parameters and only 
50 patients are taken for study. 
Clinical criteria to classify patients as exudates and transudates : 
 
If the patient had oedema legs, ascites, cardiac enlargement, radiological 
evidence of congested lungs and responded to treatment for congestive 
cardiac failure , then the diagnosis of congestive cardiac failure was made. 
When there were raised serum urea and creatinine levels along with signs 
and symptoms indicating volume overload, chronic kidney disease was 
diagnosed. 
If the patient had features of liver cell failure,ascites, spleenomegaly and 
evidence of volume overload status , chronic liver disease was diagnosed. 
 
The diagnosis of tuberculosis was made if there is cough , fever with evening 
rise of temperature, loss of weight and appetite ,sputum showing  AFB, 
ADA in pleural fluid ,chest x ray showing pleural effusion ,response to ATT. 
The diagnosis of parapneumonic effusion was made if there is cough with 
expectoration, fever with chills & rigors, chest x-ray showing pleural 
effusion,  bacteria in pleural fluid/sputum. 
The diagnosis of malignant pleural effusion was made if there is Pleural fluid 
cytology, Pleural biopsy, demonstration of primary sites. 
  
Study protocol : 
 Patients with clinical and radiological evidence of pleural effusion 
are to be included in the study  
 Then  they are classified in to exudates and transudates on the basis 
of the clinical , radiological and biochemical evaluation  . 
 In all the patients following investigation are done to classify them 
as exudates and transudates 
 Pleural fluid bilirubin & Serum Bilirubin , Pleural fluid cholesterol, 
Pleural fluid total protein are estimated and the patients are 
classified in to exudates and transudates. 
 Then the patients are classified in to exudates and transudates on 
the basis of Light’s criteria. 
 Now the classification of exudates and transudates done on the 
basis of Total Pleural fluid bilirubin and its ratio to serum , Pleural 
fluid cholesterol , Pleural fluid Total protein  are compared with 
results of the classification of exudates and transudates done on the 
basis of  Light’s criteria. 
 Sensitivity , specificity , Positive predictive value , negative 
predictive value ,  diagnostic accuracy  of each tests are calculated  
. 
  
Age   and sex distribution of the population in our study is as follows : 
82% of the study subjects were in the age group of 51-70yrs  while the 16% 
were in the age group of 41-50yrs. 
Majority of the study subjects were males (58%) while remaining 42% were 
females. 
 
Exudates and transudates distribution in our study is as follows : 
In our study about 56% of the study subjects were exudates while 44%  were 
transudates . 
Among the exudates , about 50 % of study groups have tuberculosis , 35.72 
% have malignancy and 14.28 % have parapneumonic effusions. 
Among the transudates , about 50 % of study groups have tuberculosis , 
35.72% have malignancy and 14.28 % have parapneumonic effusions. 
Pleural fluid bilirubin , Serum Bilirubin , Pleural fluid cholesterol, Pleural 
fluid total protein , Serum total protein , Pleural fluid LDH , Serum LDH  are 
estimated. 
 
 
  
Pleural fluid Bilirubin , Cholesterol , Total protein :  
Any serous membrane inflammation often leads to increased capillary 
permeability and this enables the diffusion of high molecular weight 
bilirubin , protein . 
The permeability of pleura is increased due to “serum leakage” and this leads 
to the accumulation of cholesterol in exudative pleural effusion . 
In our study to diagnose exudates the following parameters are used : 
A pleural fluid bilirubin of more than 0.48 mg / dL , 
A pleural fluid bilirubin to serum bilirubin ratio of more than 0.62 , 
A pleural fluid cholesterol of more than 60 mg / dL , 
A pleural fluid total protein more than 3 g/dL . 
Results : 
By applying  Light’s criteria in patients with exudative pleural effusion 
classified clinically , 85.72 % of the cases were correctly diagnosed as 
exudative  pleural effusion. 
By applying  Pleural fluid Bilirubin in patients with exudative pleural 
effusion classified clinically , 82.14 % of the cases were correctly diagnosed 
as exudative pleural effusion. 
  According to Pleural fluid  / Serum Bilirubin ratio , patients with exudative 
pleural effusion classified clinically, 96.42 % of the cases were correctly 
diagnosed as exudative pleural effusion. 
 By applying  Pleural fluid cholesterol to patients with exudative pleural 
effusion classified clinically , 75% of the cases were correctly diagnosed as 
exudative pleural effusion 
According to Pleural fluid Total Protein , patients with exudative pleural 
effusion classified clinically, 92.85% of the cases were correctly diagnosed 
as exudative pleural effusion. 
 
In our study by applying the Lights criteria, about 14.28 % of  exudative 
pleural effusion was misclassified  as  transudative, and by applying Pleural 
fluid Bilirubin and Pleural fluid cholesterol , the misclassification was  17.86 
% and 25 % respectively . Whereas  by Pleural fluid  / Serum Bilirubin ratio 
, the misclassification was only 3.58 %. Also 7.15 % of exudates were 
misclassified as transudates , when  Pleural fluid Total Protein was applied. 
By applying  Light’s criteria in patients with transudative pleural effusion 
classified clinically , 90.90 % of the cases were correctly diagnosed as 
transudative pleural effusion. 
 By applying  Pleural fluid Bilirubin in patients with transudative pleural 
effusion classified clinically , 86.36 % of the cases were correctly diagnosed 
as transudative  pleural effusion. 
 According to Pleural fluid  / Serum Bilirubin ratio , in patients with 
transudative pleural effusion classified clinically, 90.90 % of the cases were 
correctly diagnosed as transudative pleural effusion. 
 By applying  Pleural fluid cholesterol to patients with transudative pleural 
effusion classified clinically , 86.36 % of the cases were correctly diagnosed 
as transudative pleural effusion . 
According to Pleural fluid Total Protein  to patients with transudative pleural 
effusion classified clinically, 95.45% of the cases were correctly diagnosed 
as transudative  pleural effusion. 
In our study by applying the Lights criteria, about 9.10 % of  transudative 
pleural effusion was misclassified  as  exudative, and by applying Pleural 
fluid Bilirubin and Pleural fluid cholesterol , the misclassification was  13.64 
% and 13.64 % respectively . Also 9.10 % of  transudates were misclassified 
as exudates , when Pleural fluid  / Serum Bilirubin ratio  was applied. 
Whereas  by Pleural fluid Total Protein, the misclassification was only  
4.55 %. 
Among the  parameters used most specific test to classify an exudative 
pleural effusion from a transudative pleural effusion is pleural fluid total 
 protein which is  95.45 %  and most sensitive test is pleural fluid / serum 
bilirubin ratio which is 95.45 %. The positive predictive value, negative 
predictive value and diagnostic accuracy to classify an exudative pleural 
effusion from a transudative pleural effusion is higher for pleural fluid total 
protein  which is 96.29 % , 95.23 % , 94 % respectively . 
The sensitivity , specificity , positive predictive value, negative predictive 
value and diagnostic accuracy of Light’s criteria  are 85.71 % , 90.90 % , 
92.30 % , 83.33 % , 88 % respectively . 
 
 
In a study conducted by  Gupta K. B .,Depts.of Tuberculosis & Chest 
Diseases  
Pt.B.D.Sharma Post Graduate institute of Medical Sciences, Rohtak, 
Haryana, A total of 80 patients were classified on the basis of clinical 
radiological and biochemical evaluation into transudates and exudates. 
Assessment of efficacy of pleural fluid bilirubin (P BIL) , pleural fluid 
bilirubin/serum bilirubin ratio (P/S BIL) and  Light's criteria to correctly 
classify transudates and exudates were done. On the basis of pleural fluid 
bilirubin and pleural fluid bilirubin / serum bilirubin ratio, 78% of 
misclassified transudate by Light's criteria and 84% of misclassified 
exudates were accurately diagnosed. For Pleural fluid Bilirubin , a positive 
predictive value of 91% and a negative predictive value of 58% were found 
 by using a cut off value of 0.48mg%. Similarly, a positive predictive value of 
91% and a negative predictive value of 57% was observed , using a cut off 
value of 0.62 for Pleural fluid /Serum Bilirubin. 
 
In a study conducted by Anand K. Patel and SushmitaChoudhury 
,Department of Respiratory Medicine, Shree M.P. Shah Medical College, 
Jamnagar (Gujarat), India, 60 patients with evidence of pleural effusion 
clinically and radiologically were classified 49 as exudates and 11 as 
transudates. To distinguish transudates and exudates they used a criteria of 
pleural fluid cholesterol levels at a cut-off point of greaterthan 60 mg/dL 
and/or total protein at a cut-off point of greater than 3 g/dL.The sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value 
(NPV), were 100 percent. Using Light’s criteria for discriminating 
transudates and exudates, sensitivity, specificity, PPV and NPV were found 
to be 98%; 100%; 100% and 92%, respectively. The differences resulted 
from a mis-classification of one expected exudate as transudate 
by Light’s criteria. 
 
 
 
 
 
 DEFINITIONS 
Diagnostic accuracy : This is the probability that a randomly selected 
subject is correctly diagnosed by the test . 
Negative Predictive Value : The probability that a person who has 
tested negative on a diagnostic test (T−) actually does not have the 
disease (D−).  
Positive Predictive Value : This is the probability that a person who has 
tested positive on a diagnostic test (T+) actually has the disease(D+).  
Sensitivity : This is the probability that a person with disease (D+) will 
correctly test positive based on the diagnostic test (T+).  
Specificity:This is the probability that a person without disease (D−) 
will correctly test negative based on the diagnostic test (T−).  
D – Disease  ., T – Test 
 
 
 
 
 
 
 
 CONCLUSION  
 
Many decades Light ‘s criteria has been used widely to differentiate 
exudative from transudative pleural effusion. But it also misclassifies 25 % 
of transudates as exudates , so there is a need to identify new parameters 
which will prove to be superior or supportive to the present available array of 
tests. 
From our study we came to known that there was no statistically significant 
difference among various criterias in classifying pleural effusion as exudates 
and transudates. 
The misclassification of exudates and transudates by various criteria when 
compared to Light’s criteria is not statistically significant as p value is <0.05. 
 
From our study we came to a conclusion that to classify an exudative pleural 
effusion from a transudative pleural effusion  
- most specific test is pleural fluid total protein and  
- most sensitive test is pleural fluid / serum bilirubin ratio .  
The positive predictive value, negative predictive value and diagnostic 
accuracy is higher for pleural fluid total protein . 
 
 To conclude, though Light's criteria remains as gold standard to differentiate 
transudates and exudates, in cases where there is a mismatch between 
clinical diagnosis and the outcome from Light's criteria, pleural fluid 
bilirubin / serum bilirubin ratio and pleural fluid total protein evaluation may 
add to the diagnostic accuracy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SUMMARY  
 
 The classic criteria of differentiating an exudate from a transudate is Light’s 
criteria. Over the last few years, it has been noted that even Light's criteria 
may misclassify a significant percentage of pleural effusions.  
The objective of the present study was to evaluate the usefulness of Total 
Pleural fluid Bilirubin and its ratio to serum levels , Pleural fluid Cholesterol 
and Pleural fluid Total Protein level in classifying pleural effusions as 
exudates and transudates  with Light’s criteria as the gold standard . 
From our study it is evident that most specific test to classify an exudative 
pleural effusion from a transudative pleural effusion is pleural fluid total 
protein which is  95.45 %  and most sensitive test is pleural fluid / serum 
bilirubin ratio which is 95.45 %. The positive predictive value, negative 
predictive value and diagnostic accuracy is higher for pleural fluid total 
protein  which are 96.29 % , 95.23 % , 94 %  respectively . 
The sensitivity , specificity , positive predictive value, negative predictive 
value and diagnostic accuracy of  pleural fluid bilirubin and pleural fluid 
cholesterol was not superior to Light ‘s criteria . 
The pleural fluid /serum bilirubin ratio , pleural fluid total protein are 
very effective in differentiating exudative and transudative pleural 
effusion. 
  
Limitations of the study : 
1.Shorter study period and smaller study sample. 
2.The various parameters studied are neither combined with others nor 
with the Light’s criteria . 
3.Different levels of the Pleural fluid  bilirubin , Pleural fluid  / Serum 
Bilirubin ratio, Pleural fluid cholesterol , Pleural fluid total protein are 
not tried in this study . 
 
Further recommendations : 
1. A longer study period and a larger study sample should be considered in 
the future . 
2. Combination of  Pleural fluid  bilirubin , Pleural fluid  / Serum Bilirubin 
ratio, Pleural fluid cholesterol , Pleural fluid total protein with other 
parameters of the Light’s criteria . 
3. Another study on varying levels of Pleural fluid  bilirubin , Pleural fluid  / 
Serum Bilirubin ratio, Pleural fluid cholesterol , Pleural fluid total protein 
which will give the highest accuracy in detecting exudative effusions . 
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PROFORMA 
Name :     Age/Sex/Occupation: 
Presenting complaints: 
H/o  Fever, chest pain , cough & expectoration, hemoptysis ,dyspnea, Loss 
of weight, Loss of Appetite. Etc. 
Past history: 
H/o Tuberculosis, Chronic liver disease, coronary artery disease, chronic 
kidney disease 
Clinical examination: 
General examination: 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,  
Vitals: PR, BP, RR, SpO2, Temperature 
Systemic examination:  
CVS: 
 RS:  
Abdomen : 
 CNS: 
LABORATORY INVESTIGATIONS : 
1.Pleural fluid bilirubin & Serum Bilirubin 
2.Pleural fluid cholesterol  
3.Pleural fluid total protein & Serum Protein 
4.Pleural fluid LDH & Serum LDH 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
CHF – Congestive Heart Failure 
Pro -BNP – Pro Brain Natriuretic Peptide 
LDH-Lactate dehydrogenase 
PF-pleural fluid 
Sr-serum 
Pro-protein 
Alb-albumin 
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1 MOHAN 45 M CCF 2.7 6.1 
0.44 156 306 0.51 0.3 0.9 0.33 30 
2 PANDIARAJAN 46 M 
CCF 
2.9 5.6 
0.51 132 288 0.45 0.52 0.9 0.57 65 
3 IYYAMMAL 43 F 
CCF 
2.9 6.4 
0.45 45 159 0.28 0.32 0.8 0.4 41 
4 AYYAVU 52 M 
CCF 
2.5 6.2 
0.4 116 250 0.46 0.3 0.6 0.52 33 
5 LAKSHMANAN 62 M 
CCF 
2.3 6.4 
0.35 129 296 0.43 0.38 0.7 0.54 21 
6 CHANDRAN 57 M 
CCF 
2.9 6.5 
0.44 112 220 0.51 0.33 0.8 0.41 29 
7 KANAGA VALLI 55 F 
CCF 
2.2 6.5 
0.34 28 91 0.31 0.35 0.6 0.58 31 
8 JAMUNA 53 F 
CCF 
2.6 6.2 
0.42 59 146 0.4 0.26 0.6 0.43 18 
9 SELVA RANI 49 F 
CCF 
2.8 5.2 
0.53 98 189 0.51 0.27 0.6 0.45 30 
 
10 
 
NEHRU 
 
65 
 
M 
CCF  
2.6 
 
6.1 
0.42 57 110 0.51 0.5 0.7 0.71 25 
11 
BAGHAYA 
LAKSHMI 57 F 
Hepatic 
hydrothorax 2.9 6.4 
0.45 69 156 0.44 0.42 0.8 0.52 22 
12 MUTHU MANI 38 M 
Hepatic 
hydrothorax 2.8 6.5 
0.43 116 216 0.53 0.28 0.7 0.4 36 
13 JAYA LAKSHMI 63 F 
Hepatic 
hydrothorax 3.2 6.5 
0.49 97 193 0.5 0.41 0.7 0.58 26 
14 SIVA SANKARI 49 F 
Hepatic 
hydrothorax 2.6 6.7 
0.38 149 320 0.46 0.26 0.8 0.32 73 
15 BASHEER AHMEED 57 M 
Hepatic 
hydrothorax 2.3 6.4 
0.35 133 287 0.46 0.38 0.7 0.54 16 
16 MANIKANDAN 58 M 
Hepatic 
hydrothorax 2.6 5.9 
0.44 41 142 0.28 0.28 0.6 0.46 34 
17 IRULAYI 35 F 
Hepatic 
hydrothorax 2.6 5.8 
0.43 26 98 0.26 0.31 0.8 0.38 46 
18 MARI MUTHU 63 M 
Hepatic 
hydrothorax 2.5 5.7 
0.44 35 116 0.31 0.26 0.8 0.32 69 
 
 
19 
 
 
SONAI MUTHU 
 
 
59 
 
 
M 
 
 
CKD 
 
 
2.5 
 
 
5.9 
 
0.45 
 
19 
 
85 
 
0.22 
 
0.52 
 
0.8 
 
0.65 
 
32 
20 ARJUNAN 60 M 
CKD 
2.1 6.5 
0.31 56 132 0.42 0.27 0.5 0.54 40 
21 ANGARYARKANNI 55 F 
CKD 
2.1 6.6 
0.32 48 124 0.38 0.21 0.4 0.52 19 
22 ESHWAR LAL 65 M 
CKD 
2.3 6.7 
0.34 38 106 0.35 0.2 0.3 0.66 23 
23 RAJAMMAL 63 F Tuberculosis 3.8 6.1 
0.62 79 165 0.47 0.42 0.8 0.52 55 
24 PONAMBALAM 59 M Tuberculosis 3.5 6.1 
0.57 100 133 0.75 0.5 0.6 0.8 66 
25 RAGHAVAN 54 M Tuberculosis 4.4 6.1 
0.72 45 95 0.47 0.52 0.7 0.74 60 
26 MALAIKANI 64 M Tuberculosis 3.2 5.9 
0.54 106 190 0.55 0.51 0.7 0.6 72 
27 JAYAKUMAR 21 M Tuberculosis 3.6 6.1 
0.59 98 172 0.56 0.49 0.6 0.81 63 
28 PREMAVATHI 52 F Tuberculosis 3.2 5.6 
0.57 94 166 0.56 0.58 0.8 0.72 33 
29 RAJENDRAN 56 M Tuberculosis 3.3 5.5 
0.6 69 124 0.55 0.6 0.8 0.75 76 
30 GURUVAMMAL 53 F Tuberculosis 4.1 5.9 
0.69 71 137 0.51 0.51 0.7 0.72 65 
31 KUMAR 25 M Tuberculosis 3.2 6.8 
0.47 58 101 0.57 0.55 0.9 0.61 66 
32 RAMESH 65 M Tuberculosis 3.1 5.2 
0.59 66 86 0.76 0.53 0.8 0.66 45 
33 PANJU 68 F Tuberculosis 3.9 5.9 
0.66 298 387 0.77 0.56 0.9 0.62 80 
34 PALANIVEL 60 M Tuberculosis 3.6 5.3 
0.67 250 320 0.78 0.52 0.7 0.74 71 
35 MEENAKSHI 61 F Tuberculosis 4.1 6.1 
0.65 114 235 0.48 0.6 0.8 0.75 61 
36 RANJITHAM 30 F Tuberculosis 3.1 6.4 
0.48 99 219 0.45 0.5 0.6 0.83 49 
37 ARUMUGAM 32 M Pneumonia 3.5 6.5 
0.53 306 421 0.72 0.61 0.9 0.67 69 
38 GANESAN 57 M Pneumonia 3.2 6.6 
0.48 112 216 0.51 0.58 0.8 0.72 48 
39 VIMALA 36 F Pneumonia 3.4 6.1 
0.56 341 487 0.71 0.55 0.6 0.9 78 
40 SUMATHI 52 F Pneumonia 2.9 6.5 
0.58 221 362 0.61 0.44 0.6 0.73 66 
41 KANNAN 52 M Malignancy  3.2 5.9 
0.54 74 116 0.63 0.33 0.5 0.66 66 
42 SANTHA RAM 60 M Malignancy  3.1 5.8 
0.53 102 154 0.66 0.5 0.8 0.62 68 
43 VASANTHA 39 M Malignancy  2.7 5.9 
0.45 82 198 0.41 0.33 0.5 0.72 61 
44 INDRA 68 F Malignancy  3.4 6.3 
0.53 68 85 0.79 0.51 0.8 0.63 45 
45 KASIRAJAN 75 M Malignancy  3.3 6.1 
0.54 41 79 0.51 0.41 0.6 0.68 78 
46 THAVAMANI 47 F Malignancy  3.1 5.9 
0.52 95 166 0.57 0.53 0.7 0.75 71 
47 MYTHILI 52 F Malignancy  3.2 5.8 
0.54 86 109 0.78 0.55 0.8 0.68 33 
48 VASUDEVAN 49 M Malignancy  3.5 5.6 
0.62 56 141 0.39 0.51 0.7 0.72 62 
49 NARAYANAN 62 M Malignancy  3.2 5.8 
0.54 112 163 0.68 0.59 0.9 0.65 70 
50 KALAISELVI 67 F Malignancy  3.4 6.2 
0.54 59 92 0.64 0.54 0.7 0.77 63 
 
  
 
 
  
 
 
 
 
